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The initiation and maintenance of reproductive capacity in humans is dependent upon 
pulsatile secretion of the hypothalamic hormone gonadtropin-releasing hormone, GnRH.  
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder that results from the 
failure of the normal episodic GnRH secretion, leading to delayed puberty and infertility.  
CHH can be associated with an absent sense of smell, also termed Kallmann syndrome, or 
with other anomalies. CHH is characterized by rich genetic heterogeneity, with mutations in 
more than 30 genes identified to date acting either alone or in combination. CHH can be 
challenging to diagnose, particularly in early adolescence where the clinical picture mirrors 
that of constitutional delay of growth and puberty. Timely diagnosis and treatment will 
induce puberty, leading to improved sexual, bone, metabolic and psychological health. In 
most cases, patients require lifelong treatment yet a significant portion of male patients 
(around 10-20%) exhibit a spontaneous recovery of their reproductive function. Finally, 
fertility can be induced with pulsatile GnRH treatment or gonadotropin regimens in a 
majority of patients.  In summary, this review is a comprehensive synthesis of the current 
literature available regarding the diagnosis, patient management and genetic foundations of 
congenital hypogonadotropic hypogonadism relative to normal reproductive development. 
Essential points  
• Minipuberty is an important window to assess the activity of the HPG axis, especially in male 
neonates with cryptorchidism and/or micropenis in order to diagnose neonatal CHH.  
• Currently, it is difficult to differentiate CHH from CDGP in early adolescence, as these two 
conditions have nearly identical clinical presentations and biochemical profiles.  
• While awaiting the development of novel biomarkers, testicular volume and circulating serum 
inhibin B levels may be most reliable parameters to differentiate CHH from CDGP to date.  
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• Given the complex genetics of CHH including oligogenicity, reduced penetrance and variable 
expressivity, defining a clear genetic diagnosis for each patient is often daunting.  
• Treatments are effective to induce secondary sexual characteristics in both sex, however the 
role of gonadotropin therapy during the neonatal and adolescence periods remains unclear.  
• Infertility in CHH patients can often be treated successfully with a combination of 
gonadotropins or pulsatile GnRH, although patients with the most severe form of GnRH deficiency 
may benefit from a pretreatment with FSH.  
1.  Introduction 
Puberty is one of the most striking postnatal developmental processes in humans. It is 
accompanied by the acquisition of secondary sexual characteristics, the onset of fertility, the 
attainment of adult height and imporant psychosocial changes (1).  Puberty is initiated by the 
re-awakening of the hypothalamic-pituitary-gonadal (HPG) axis following a relative 
quiescence during childhood (2). Pulsatile secretion of gonadotropin-releasing hormone 
(GnRH) by specialized neurons in the hypothalamus stimulates the release of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) by the pituitary, which in turn 
stimulate steroidogenesis and gametogenesis in the gonads. Notably, the onset of puberty is 
preceded by two periods of the hypothalamic-pituitary-gonadal (HPG) axis activity: the fetal 
life and infancy (minipuberty). 
The timing of puberty varies largely in the population, and 50-80% of this variation is 
genetically determined (3-5). Delayed puberty is defined as a delay of pubertal onset or 
progression greater than 2SD compared to the population mean (6). Constitutional delay in 
growth and puberty (CDGP) is the most frequent cause of delayed puberty (2% in the general 
population), and is related to a transient GnRH deficiency. In CDGP, puberty eventually 
begins and is completed spontaneously. In contrast, congenital hypogonadotropic 
hypogonadism (CHH) is a rare genetic disease caused by GnRH deficiency. It is 
characterized by absent or incomplete puberty with infertility (7). This infertility is medically 
treatable, and in fact CHH is one of the few treatable causes of infertility in males. When 
CHH is associated with anosmia, it is termed Kallmann Syndrome (KS).   
Considerable differences exist in the terminology surrounding the permanent forms of 
GnRH deficiency in humans, with idiopathic hypogonadotropic hypogonadism (IHH), 
isolated GnRH deficiency (IGD), and congenital hypogonadotropic hypogonadism (CHH) 
being used almost interchangeable.  IHH was the first terminology to appear in print (8), 
however “idiopathic” is typically reserved for diseases which appear spontaneously or whose 
cause is undetermined (9). Several molecular etiologies have since been described underlying 
this disorder resulting in the less frequent use of IHH. Isolated GnRH deficiency was first 
reported in the literature in 1986 (10) and is still widely used in North America. However, the 
disorder can be due to mutations in the GnRH receptor resulting in a state of GnRH resistance 
rather than deficiency. CHH was first used in 1980 (11). Although the diagnosis is often 
made during adolescence or after, the disease is mostly due to developmental defects (i.e. 
defects in GnRH neuron migration or in the maturation of the GnRH neuronal network) and 
often associated with congenital features. The term CHH is commonly used especially in 
Europe, and will be used in this review. 
In this review, we describe the spectrum of clinical presentations in CHH, the diagnostic 
evaluations including the challenge of differentiating CHH from CDGP, the advances in 
genetic diagnosis and therapy for CHH, as well as the consequences of a delay in diagnosis. 
Finally, we discuss the therapeutical options from different perspectives. To achieve these 
objectives, we also review the normal physiology of the HPG axis. 
2.  Fetal development of the hypothalamic-pituitary-gonadal axis  
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The HPG axis is active in the mid-gestational fetus but quiescent towards term (12). This 
restraint is removed after birth, leading to a reactivation of the axis and an increase in 
gonadotropin levels (minipuberty). 
The majority of GnRH-secreting neurons are located in the arcuate nucleus and the 
preoptic area of the hypothalamus (13). GnRH neurons are an unusual neuronal population, 
as they originate outside the central nervous system in the olfactory placode, and follow a 
complex migration route to reach their final destination in the hypothalamus (14,15). The 
complex developmental process of GnRH neurons has unfolded through both murine and 
human genetic studies (16-18).   
GnRH neurons fate specification occurs from progenitor cells in the olfactory placode at 
gestational week (GW) 5 in humans, and days 9.5 to 11 in mice (19). Subsequently, the 
GnRH neurons begin their migration from the nasal placode following the axon guidance of 
the vomeronasal nerve (VNN) and the olfactory nerve until they cross the nasal mesenchyme 
and cribriform plate. Thereafter, the GnRH neurons follow the guidance of the VNN ventral 
branch reaching the forebrain. From here, the GnRH neurons detach from the VNN axons to 
reach their final destination in the arcuate nucleus and the preoptic area of the hypothalamus. 
Subsequently, they extend their axons to the median eminence reaching the fenestrated 
blood-brain capillaries of the hypothalamo-pituitary portal vessels. By day 16 in the mice and 
around 15 weeks of gestation in human, GnRH is detected in the hypothalamus and the 
GnRH neuronal system is largely complete (18,20). 
Recently, studies of GnRH ontogeny in mice and humans using the innovative technique 
of 3DISCO optical tissue-clearing reveal the detailed dynamics of GnRH neuron ontogeny 
and migration from nasal compartment to forebrain. Notably, the number of GnRH neurons 
in the human fetal brain is much higher (~10,000) than previously anticipated (18).  
LH is detected in the human anterior pituitary by GW 9 (21), and is released into the 
circulation by GW 12 (22-24). The exact timing when pituitary gonadotropin secretion will 
come under the control of the hypothalamic GnRH is not clear. In anencephalic fetuses 
without a hypothalamus, pituitary development is normal up to GW 17-18  before it 
involutes, suggesting that hypothalamic signalling is needed for the maintenance of the 
gonadotropes from this stage (25). Fetal serum gonadotropin levels peak at mid-gestation in 
both sexes and decrease near term (26). This decline in the gonadotropins is likely due to the 
negative feedback mediated by increased placental estrogen (12). However, limited data exist 
on the hypothalamic-pituitary function in human fetuses after gestational week 22 (26). 
Females generally exhibit high circulating FSH and LH levels in the range of postmenopausal 
women, which is much higher than in male fetuses (22,23,26-29). Near term, circulating 
gonadotropin levels decrease. The latter is thought to be related to the increase of placental 
estrogens and progesterone, acquisition of sex steroids nuclear receptors by pituitary 
gonadotropic cells, and subsequent gonadal feedback (22-24,28,30). 
The differentiation of the gonads into testicles and ovaries occurs between GW 5-7. It is a 
complex process involving a critical role of the SRY gene on the Y chromosome for males.   
During GW 8, the differentiated Sertoli cells in the seminiferous tubules start to produce anti-
Müllerian hormone (AMH) under the contol of SOX9, which leads to regression of the 
Müllerian ducts (31). Placental hCG (human chorionic gonadotropin) during the first 
trimester and subsequently fetal pituitary LH from mid-gestation regulate Leydig cell 
differentiation to produce testosterone (T) from the fetal Leydig cells (32), which is needed 
for masculinization of the fetus. Testosterone is needed for the development of the male 
internal genitalia, while dihydrotestosterone produced by the enzyme 5-α reductase 2 
(SRD5A2) induces the formation of the prostate, penis and scrotum. Until mid-gestation, 
testosterone production is driven by placental hCG rather than by GnRH-induced LH 
secretion by the fetus. This is consistent with the absence of genital differentiation defects in 
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CHH. However, in the third gestational period penile growth and inguino-scrotal testicular 
descent occur, mediated in part by testosterone stimulated by GnRH-induced LH secretion 
(reviewed in (33) and (34)).  
In females, the gonads develop into an ovary in the absence of the Y chromosome. 
However, several active signalling pathways need to be present for a normal differentiation of 
the ovary (35). In addition, the differentiation of internal or external genitalia occurs 
independently of the ovaries. In the absence of AMH, the Müllerian ducts will develop into 
fallopian tubes, uterus and a portion of the vagina. In humans, primordial follicles develop in 
the fetal ovary around GW 15 (36) and are gonadotropin-independent. At this stage, the 
amount of steroid production from fetal ovaries seems minimal compared to high placental 
estrogen production (37).  
Fetal reproductive development: Implications for CHH phenotypes 
Disruption of the complex ontogeny of the GnRH neurons and olfactory system can lead to 
GnRH deficiency and, in severe cases, to CHH with or without anosmia. However, during the 
first trimester of pregnancy, which is critical for sexual differentiation, the GnRH neuronal 
system is non-functional.  Consequently, the differentiation of the genitalia in CHH is 
normal. In contrast, during late pregnancy GnRH induced LH secretion stimulates further 
penile growth and testicular descent. Thus, a higher prevalence of micropenis and 
cryptorchidism is encountered in CHH (reviewed in (34)). 
3.   Clinical presentation of CHH  
3.1  Clinical presentation of CHH during the minipuberty  
3.1.1  Normal minipuberty 
Within minutes of birth, a brief postnatal LH surge leads to an increase in testosterone levels 
during the first day of life which then subsides (38).  
After the first postnatal week, as serum placental estrogen levels have declined, increased 
pulsatile GnRH secretion (39) leads to elevated gonadotropins and sex steroid levels in both 
sexes, with peak levels observed at 1- 3 months of age (minipuberty) (40-44). During this 
time, FSH levels are higher in girls, and LH levels are predominant in boys (43). In boys, LH 
and FSH levels decrease by 6 months of age, however FSH levels remain elevated up to 3-4 
years of life in girls (12,43,45). A recent study of both full-term and pre-term infants suggests 
that gonadal feedback mediated by sex steroids, and inhibin B can influence the sexual 
dimorphism for FSH and LH levels during minipuberty (46). 
In boys, T levels start to increase after 1 week postnatally, peak between 1-3 months, and 
then decline to low prepubertal levels by approximately 6 months (12,43,45). These changes 
mirror GnRH-induced LH activation. During minipuberty, T levels correlate with penile 
growth (47), and postnatal T levels have also been associated with male-type behaviour in 
toddlers (48). In addition, acne, sebaceous gland hypertrophy and increased urinary prostate-
specific antigen levels are observed, consistent with androgen bioactivity (44,49). GnRH-
induced gonadotropin secretion stimulates the production of inhibin B (a marker of Sertoli 
cell number and function) (43) and AMH (50) and the Leydig cell product INSL3 (51). High 
inhibin B levels remain beyond 6 months of age despite the decrease in gonadotropin 
secretion (43).  
Testicular volume (TV) increases during minipuberty (12,52,53). One critical event 
during this time is the significant proliferation of immature Sertoli cells and spermatogonia 
induced by FSH, mirroring the increased levels of circulating inhibin B. On average, the 
Sertoli cell population increases from 260 x 106 at birth to 1500 x 106 by 3 months of age, 
and this increase constitutes a critical determinant for future sperm producing capacity in 
adulthood (53,54). Despite high levels of intragonadal T and the gonadotropin surge, Sertoli 
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cells and spermatogonia do not undergo differentiation and spermatogenesis is not initiated. 
During this period, Sertoli cells express low level of androgen receptors (AR) and thus 
remain immature despite increased testosterone during minipuberty (50,55,56). 
In girls, elevated gonadotropin levels result in an increase in ovarian follicular 
development (44,49). Estradiol (E2) levels also start to increase after one week of age (44) 
and are associated with increased folliculogenesis (49), and then decrease during the second 
year of life (44). The high circulating E2 levels in girls lead to palpable breast tissue during 
minipuberty (44,57). The postnatal gonadotropin surge also induces the production of the 
granulosa cell hormonal peptides inhibin B (43) and AMH (49).  
In both sexes, testosterone appears to be a significant modulator of growth during infancy 
(58) and influences neurobehavioral sexual differentiation (48). Notably, minipuberty appears 
enhanced in preterm infants and in those born small for gestational age (reviewed in (12)).   
The biological significance of minipuberty and its consequences on reproductive 
capacity are not fully understood. This period may be critical for future reproductive health, 
and thus warrants additional investigation. The exact mechanism that leads to the quiescence 
of the HPG axis after infancy remains largely unknown. The observation of a similar pattern 
of gonadotropin secretion occurs in anorchid boys indicates that the inhibition of the HPG 
axis at the end of minipuberty is independent of the gonads (59). 
3.1.2  Minipuberty: Implications for CHH phenotypes 
From a diagnostic perspective, minipuberty offers a unique window of opportunity for the 
early diagnosis of CHH (60). While there are no clear clinical signs of GnRH deficiency in 
female infants, micropenis and cryptorchidism raise a suspicion of CHH in male infants, as 
these signs may reflect the lack of activation of the HPG axis during fetal and postnatal life. 
Large retrospective studies on CHH including KS have described a frequency of 
cryptorchidism ranging from 30-50% (61,62), which is higher than the general population 
(cryptorchidism in full-term male newborns: 1-3% worldwide (63) and 9% in Denmark (64). 
This observation is consistent with the role of GnRH-induced T secretion during fetal life and 
minipuberty in testicular descent. Reports on the frequency of micropenis among CHH 
patients is variable, ranging from 20-40 % in KS patients while a frequency of 0.015% is 
reported in the general population (65-67).  
3.2  Clinical presentation of CHH during adolescence 
3.2.1  Normal puberty 
Puberty is characterized by sexual maturation, increased growth velocity, changes in body 
composition and psycho-social behavior and culminates with the acquisition of reproductive 
capacity initiated by the reawakening of the GnRH pulse generator after a relative quiescent 
period during childhood (68,69). GnRH-induced pulses of LH first occur during the night, but 
gradually increase to both day and night resulting in gonadal maturation and the completion 
of puberty (70-73). The precise mechanisms that triggers the initiation of puberty remain 
unclear. Murine studies have shown dynamic remodelling in GnRH neuron morphology 
occuring at puberty with the acquistion of more than 500 spines associated with increasing 
synaptic inputs contributing to the sharp increase in GnRH neuron activity (74). Increased 
excitatory input like glutamate or decreased inhibitory input like aminobutyric acid (GABA) 
appear to be critical for pubertal onset (75). In addition, the nature of the GnRH pulse 
generator is still a debate (76). In particular, whether GnRH neurons exhibit an intrinsic pulse 
generator or whether a neuronal network is required for pulsatile GnRH secretion remains 
unclear (77). A recent study demonstrated the key role of kisspeptin neurons located in 
arcuate nucleus in driving GnRH pulsatility in mice (78). Previous works performed in girls 
with Turner syndrome and in agonadal boys have clearly showed that the pubertal 
reactivation of gonadotropic axis is independent of the presence of functional gonads (79-83). 
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The increase in GnRH-induced gonadotropins during puberty is critical to stimulate the 
production of gametes and thus fertility. In males, FSH secretion stimulates a second wave of 
proliferation of immature Sertoli cells and spermatogonia prior to seminiferous tubule 
maturation. This process is associated with an increase in the level of inhibin B, a marker of 
Sertoli cells number and function (84). Progressively, LH stimulates Leydig cell 
differentiation and their steroidogenic capabilities leading to testosterone production. The 
concomitant stimulation of Sertoli cells by FSH and the production of intragonadal 
testosterone by LH leads to the initiation of spermatogenesis and a sharp increase in testicular 
volume consisting mainly of maturing germ cells with an increase in the diameter of 
seminiferous tubules. During this process, AMH levels start a reciprocal decrease in 
comparison to testosterone and inhibin B (85). This finding likely reflects changes in 
androgen receptor expression in immature Sertoli cells, since androgen receptors are present 
in only 2-15% of Sertoli cells until 4 years of age, whereas its expression can be observed in 
> 90% of Sertoli cells after the age of eight years (55). Notably, AMH levels begin to decline 
before any notable increase in testis size (85,86). In addition, testicular INSL3 secretion 
increases during the course of puberty with a strong correlation to LH levels (87,88).  
In girls, the early stages of follicular growth are primarily driven by intra-ovarian factors. 
However, pubertal onset is characterized by an increase in gonadotropin levels that are 
necessary for terminal maturation of the follicules leading to ovulation (89). GnRH-induced 
LH stimulates the production of androgens by the theca cells, while increased FSH is needed 
for the recruitment of ovarian follicles and the aromatisation of androgens to estradiol by the 
granulosa cells (90). AMH concentrations show only minor fluctuations during female 
puberty (91), while inhibin B, similar to boys, increases during puberty (92).   
Clinically, puberty consists of a series of changes that typically appear in a predictable 
sequence. However, considerable variation in the timing of pubertal onset exists even among 
individuals of a given sex and ethnic origin, ranging roughly from 8 to 13 years in girls (93) 
and 9 to 14 years in boys (94). Pubertal tempo also exhibits significant inter-individual 
variation with slightly faster progression rate in boys than in girls (95-97). Several studies 
have detected significant correlations between later pubertal onset and faster pubertal tempo 
in girls (98-101). The latter has been proposed as a compensatory catch-up mechanism. 
A longitudinal follow-up of 432 Caucasian girls in the United States between 9.5 and 15.5 
years old confirmed that the first detectable milestone of puberty is breast development (i.e. 
thelarche, breast Tanner stage 2). Thelarche occurs at an average of ~10 years old followed 
by the appearance of pubic hair (i.e. pubarche) 4 months later (102). Almost concommitantly 
to thelarche, growth velocity begins to accelerate. The growth spurt lasts approximately 2 
years and allows for the acquisition of approximately 18% of final height (103). Peak height 
velocity (PHV) occurs at an average of 11.5-12 years old, approximately one year after 
thelarche (96). Menarche occurs approximately 6 months later (99). The median time 
between the onset of puberty and menarche is approximately 2.5  years (99,104). Secondary 
sexual characteristics development (breast Tanner stage 4 and/or pubic hair stage 5) is 
completed approximately 1.5 year after menarche. 
In boys, testicular enlargement (volume ≥ 4 ml) is the first clinically detectable sign of 
puberty, occuring at ~11.5 years, and approximately 6-12 months before penis growth (i.e. 
genital Tanner stage 3) and pubarche (94,105,106). The growth spurt begins subsequently 
with a PHV occuring at age 13.5.  In a 7-year longitudinal study, spermatarche, defined as the 
presence of spermatozoa in the urine, was detected at a median age of 13.4 years (range, 
11.7-15.3 years) (107). This suggests that spermatarche is a relatively early pubertal event, 
often preceding PHV. Another milestone of male puberty is the age of first ejaculation. A 
study of 1582 boys from Bulgaria showed an average age of 13.3 ± 1.1 years for first 
ejaculation (108). Voice breaking in males is also a distinct event usually occurring between 
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Tanner stages G3 and G4 (97,109). A retrospective longitudinal study of 463 Danish choir 
boys showed voice break at an average of 14.0 years (range 13.9-14.6 years) (110). Complete 
pubertal development is achieved at an average age of 15.5 years or earlier according to the 
latest European data (94).  
Common hallmarks of puberty in both genders include bone mass acquisition, changes in 
body composition, and brain development. Bone changes during puberty are detailed in 
Section 8.5.1. Changes in body composition have different patterns in girls and boys. In early 
puberty, the increase in body mass index (BMI) is driven primarily by changes in lean body 
mass, whereas increases in fat mass are the major contributor in later puberty (111). Gender 
differences are evident with girls exhibiting a higher proportion of fat mass gain than boys at 
all stages, with annual increases in BMI largely due to increases in fat mass after the age of 
16 years (112). Hormonal changes during puberty also affect the brain by promoting its 
remodeling and completing the sexual maturation that begins in the prenatal and early 
postnatal life (113). This has been clearly demonstrated in animal models (114), and is 
supported by positive correlations between pubertal markers (physical or hormonal) and 
structural magnetic resonance imaging (MRI) changes in grey and white matter development 
in humans, even after removing the confounding effect of age (113). 
3.2.2  Trends in pubertal onset and progression 
It is clear that the average age of menarche has decreased significantly between the 19th and 
the mid-20th centuries in many countries (115). This secular trend is associated with 
improved general health, nutrition, and lifestyle. A large Danish study comparing puberty in 
girls in two different periods (1991–1993 and 2006–2008) demonstrated earlier breast 
development in the girls born more recently, even when adjusting for BMI. However, the 
central activation of puberty was not proven (93). This advance in breast development might 
be due to exposure to endocrine disruptors or other factors (116). Studies on the age of 
puberty in boys have also suggested an advanced age of pubertal onset although additional 
research is required to confirm this trend. There are racial differences in pubertal onset (117), 
though this difference is probably decreasing (118).  
3.2.3  Delayed puberty  
Delayed puberty is defined as pubertal onset occuring at an age of 2 or 2.5 SD later than the 
population mean. The traditional clinical cut-offs applied are 14 years for boys (testicular 
volume < 4 ml) and 13 years for girls (absence of breast development) (6). This definition, 
however, only focuses on the onset of puberty without considering progression of puberty as 
diagnostic criteria. Recently, the use of a puberty nomogram evaluating not only the pubertal 
onset but also pubertal progression (in SD/year) led to a more accurate description of normal 
puberty and its extremes (precocious and delayed puberty) (119) (Figure 1).The most 
common cause of delayed puberty in both sexes is the constitutional delay of growth and 
puberty (CDGP), which is often considered as an extreme variant of normal pubertal timing. 
In a large series of 232 patients with delayed puberty investigated in a tertiary US referral 
center, CDGP accounted for 65% of cases in boys and 30% of girls (120) presenting with a 
delay in puberty. Relatively similar estimates (82% for boys and 56% for girls) were reported 
in a recent European study encompassing 244 patients with delayed puberty (121). Though its 
pathophysiology is not fully understood, CDGP has a clear genetic basis, as 50-75% of 
CDGP patients have a positive family history (122).  
CDGP is a diagnosis of exclusion. Other underlying causes of delayed puberty should be 
actively investigated and ruled out including hypergonadotropic hypogonadism (e.g. 
Klinefelter syndrome or Turner syndrome), permanent hypogonadotropic hypogonadism (e.g. 
CHH, tumors, infilitrative diseases) and functional hypogonadotropic hypogonadism (e.g. 
systemic illness, anorexia nervosa, excessive exercise). In particular, the differential 
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diagnosis between CDGP and CHH in adolescence is particularly difficult as discussed in 
detail in Section 7.3. Management options include expectant observation versus short-term 
sex steroid replacement (6). The latter targets primarily the induction of secondary sexual 
characteristics in order to alleviate psychosocial distress due to pubertal delay and/or short 
stature.  
3.2.4  Hallmarks of CHH in adolescence 
In males  
In adolescence, CHH male patients seek medical attention for absent or minimal virilization, 
low libido, and erectile dysfunction (123). In 75% of CHH patients, puberty never occurs, 
leading to severely reduced testicular volume (< 4 ml) and the absence of secondary sexual 
characteristics (i.e. sparse facial and body hair, high pitched voice). In this group (absent 
puberty), micropenis and/or cryptorchidism are commonly observed. In contrast, 25% of 
CHH patients exhibit partial GnRH deficiency as evidenced by some spontaneous testicular 
growth (TV > 4 ml) with little virilization, which subsequently stalls (61,124). Most patients 
do not have any ejaculate in the setting of severe hypogonadism. Indeed, testosterone is 
needed for seminal and prostatic fluids production and optimal ejaculate volume.   
The majority of CHH patients have eunuchoidal proportions with arm spans typically 
exceeding height by ≥ 5 cm, reflecting the delayed closure of the epiphysis of long bones in 
the absence of gonadal steroids. The lack of increased sex steroids levels leads to steady 
linear growth (125) without a growth spurt, however final height is rarely affected (126). 
Several studies report that adult height in CHH men exceeds the height of healthy control 
men (127-129). Other studies show that CHH adolescents, on average, achieve their mid-
parental height (126,130). Studying 41 CHH men, a positive correlation was found between 
the delay of puberty prior to treatment and adult height, such that 6 years or more of pubertal 
delay was associated with ~5 cm greater adult height (128). On the other hand, Dickerman et 
al. reported the growth of 50 adolescents with CHH and found no differences in the achieved 
normal adult height between boys who were referred before 16 years of age or thereafter 
(129). Boys in both groups exceeded their predicted final height by 4.9 cm (referred before 
16 years of age), and by 6.3 cm (referred after 16 years). 
Typical changes of body composition in CHH boys include decreased muscle mass and 
female body habitus with a gynoid pattern of fat distribution. Mild gynecomastia can be seen 
in untreated patients due to the imbalance of the testosterone/estradiol ratio. Bone maturation 
is impaired, with delayed bone age and lower bone density observed relative to peers. There 
are no reported data on bone micro-architecture of CHH males, and the risk of fracture is 
difficult to assess given the lack of large multi-center prospective studies on bone health in 
CHH.  
In females 
The most prevalent complaint is primary amenorrhea in nearly 90% of CHH women (131-
134). Less than 10% of CHH women had some menstrual bleeding (131,133,135), which in 
most cases involved one or two episodes of bleeding during adolescence (primary-secondary 
amenorrhea) before chronic amenorrhea sets in (131-134). Chronic oligomenorrhea has been 
reported, although at a considerably low frequency (136,137). 
Several studies have shown that absent breast development is observed in a minority of 
CHH women prior to estrogen replacement therapy (131-133). Only one single multicenter 
retrospective study described absent breast development in the majority of CHH women 
(134). However, this study included only female CHH patients without breast development. 
Pubarche also shows great variability, ranging from absent to almost normal pubic hair 
(131,133). Varying degrees of GnRH defciency may impact ovarian androgen production 
differently (132) (see below). Further, adrenarche leading to increase production of adrenal 
androgen (i.e. DHEA, androstenedione) could also contribute to pubarche (132,138).  
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Linear growth and final height in women with CHH has been evaluated in relatively few 
studies (129,139). The scant published data indicate that the final height in these women is 
similar to that of the reference population. In Dickerman’s series, the growth of 16 females 
with CHH was unremarkable (129), whereas a slight mid-childhood deceleration in the 
growth rate of girls carrying FGFR1 mutations was recently reported (124,139).  
3.3  Clinical presentation of CHH in adulthood 
Although the clinical presentation of CHH in adolescence is more common, some patients do 
not seek medical attention until adulthood. At this point, low libido, infertility, or less 
commonly bone loss and fractures are the most common complaints. Although male patients 
usually exhibit prepubertal or small degrees of spontaneous testicular growth, larger testicular 
volume with preserved spermatogenesis is observed in a subset of male patients (called 
‘fertile eunuch syndrome’). These patients exhibit low serum levels of testosterone in the 
setting of detectable gonadotropins. The presence of low amplitude and/or low frequency or 
sleep-entrained GnRH pulses is thought to be sufficient to support intra-testicular testosterone 
production, but unable to achieve normal circulating testosterone levels for full virilization 
(140). Very rarely, CHH is diagnosed at older age. Recently, Patderska et al. described six 
cases of men who were diagnosed with CHH after 50 years of age, and who had long-term 
uncorrected hypogonadism (141). These patients exhibited adverse health events such as 
osteoporosis (6/6), hypercholestelemia (4/6) and anemia (2/6). Body composition and 
cardiovascular events were not documented. To the best of our knowledge, there is no report 
on undiagnosed female patients until age of menopause. Further, data on the natural history 
of CHH in older men and women is lacking. 
In addition, a small subset of patients present with adult-onset hypogonadotropic 
hypogonadism (AHH). These patients report normal pubertal development followed later by 
the complete inhibition of the HPG axis leading to severe hypogonadotropic hypogonadism 
(HH). No central nervous system abnormalities or risk factors for functional GnRH 
deficiencies have been identified (142), and follow-up studies in AHH have shown the 
absence of recovery (143).  
The psychological impact of CHH is often neglected. The absence of sexual hormones 
and its impact on physical appearance constitutes a major source of psychological distress for 
hypogonadal males (144). Specifically, CHH can be accompanied by anxiety and depression 
(124,145), and these symptoms are frequently underestimated by physicians (146). Low self-
esteem and altered body image have also been reported (147) and can prevent adequate 
psychosexual development (124,148). Similarly, pschological distress is observed in female 
CHH patients. A recent online survey suggests a negative perception of CHH women on their 
health status, with a tendency towards depression (149). This same study suggests that care 
providers often do not adequately address these issues, and according to patients even have a 
tendency to dismiss the psychological consequences of their poor pubertal development 
(149). It is also quite possible that the erroneous perception of their potential infertility (see 
below) is also a major contributor to their malaise.  
3.4  CHH reversal 
Although CHH was previously considered as a life-long condition, it is now known that a 
subset of CHH patients spontaneously recover function of their reproductive axis following 
treatment (150-153). Reversibility occurs in both male and female CHH patients, and appears 
to be more common (~10-20% in males, and a few case reports for females) than previously 
thought (150-152). Patients with reversal span the range of GnRH deficiency from mild to 
severe, and many harbor mutations in genes underlying CHH. However, to date there are no 
clear clinical factors for predicting reversible CHH. Similarly, the genetic signature for 
reversal remains unclear, although an enrichment of TAC3/TACR3 mutations has been 
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observed in one series of patients (151,154). Importantly, recovery of reproductive axis 
function may not be permanent, as some patients experience a relapse to a state of GnRH 
deficiency (151,153), therefore long-term monitoring of reproductive function is needed. 
Thus, CHH patients experiencing reversal (i) represent the mild end of the clinical spectrum, 
(ii) demonstrate the plasticity of the GnRH neuronal system, and (iii) highlight the 
importance of the effects of environmental (or epigenetic) factors such as sex steroid 
treatment on the reproductive axis. Indeed, treatment with sex steroids was the only common 
denominator in patients experiencing reversal.  Normalization of the sex steroid milieu may 
trigger maturation of the GnRH neuronal network at least in a subgroup of patients, as the 
expression of critical genes for GnRH ontogeny are sex steroid responsive (155,156). 
3.5  CHH-associated phenotypes   
CHH can be associated with non-reproductive phenotypes. Anosmia (i.e. lack of sense of 
smell) is observed in approximately 50% of CHH cases (157,158), and this co-occurrence is 
termed Kallmann syndrome (KS). The interconnected link between the GnRH and olfactory 
systems during early developmental stages explains this association (see above, Section 2) 
(159).  
Other phenotypes are also associated with CHH, although at a lower prevalence. They 
include mirror movements (synkinesia), unilateral renal agenesis, eye movement disorders, 
sensori-neural hearing loss, midline brain defects (including absence corpus callosum), cleft 
lip/palate, dental agenesis, skeletal defects, and cardiovascular defects (7,157,158,160) 
(Figure 2). Three large studies have evaluated the prevalence of these associated phenotypes 
in CHH, although these studies were retrospective without a systematic evaluation for CHH 
associated-phenotypes (157,158,160). A summary of these studies along with the frequency 
of these phenotypes in the general population can be found in Table 1. The presence of 
specific phenotypes can lead to the diagnosis of syndromic forms of CHH (e.g. CHARGE 
syndrome, Waardenburg syndrome, and 4H syndrome). A search for hypogondotropic 
hypogonadism in OMIM (http://www.omim.org/) finds 46 complex syndromes which include 
this trait. In this review, we have compiled a table of syndromes having both a clinical and 
genetic overlap with CHH (Table 2).  
4. Epidemiology 
There is no rigorous epidemiological study on the prevalence of CHH. Two historical studies 
examining military records provided some estimation of the prevalence of this disease. One 
study examined 600,000 Sardinian conscripts during their military checkup, and identified 
seven cases with normal karyotype presenting bilateral testicular atrophy and anosmia 
(considered as KS cases), and thus estimated that the prevalence of KS is 1 in 86,000 in that 
population (192). A second study identified 4 cases of hypogonadotropic hypogonadism 
among 45,000 French men presenting for military service, and thus determined that the 
prevalence of CHH is 1 in 10,000 (193). There is no study on the prevalence of female CHH. 
In the series from the Massachusetts General Hospital of 250 consecutive CHH cases, the 
male to female ratio is 3.9 to 1. However, this ratio drops to 2.3 to 1 when the familial cases 
were analyzed separately (140). A recent epidemiological study examining the discharge 
registers of all five university hospitals in Finland estimated the prevalence of KS is 1:48,000 
in the Finnish population, with a clear difference between males (1:30,000) and females 
(1:125,000) (65).  
Bias regarding the reduced prevalence of CHH in females 
The prevalence of CHH has historically been considered to be skewed towards a male 
predominance (male/female ratio of  5:1) (157,158). Recent work suggests that the sex ratio 
is closer to 2:1 (133,134). Further, analysis of sex ratio for CHH in families with autosomal 
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inheritance demonstrates that the sex ratio is close to being equal (194,195). Importantly, 
partial congenital hypogonadotropic hypogonadism may still be underdiagnosed due to subtle 
clinical presentation that resembles functional hypothalamic amenorrhea (131,196). 
Several reasons could help to explain the underdiagnosis of CHH females: 
(i) Over the last decade, there has been a refinement of the spectrum of GnRH deficiency in CHH in both 
males and females, as the hallmarks of CHH were for a longtime absent puberty, leading to an 
underevaluation of the prevalence of CHH in the past (131,133).  
(ii) In the 1990s, it was thought that X-linked CHH is prevalent and thus that female CHH patients were 
rare. This dogmatic view was progressively challenged by the first descriptions of female CHH patients 
harboring biallelic GNRHR mutations, with variable degrees of breast development (135,137,197,198). 
Later, a variable degree of pubertal development was described for female CHH carrying mutations in 
autosomal genes (e.g. FGFR1, PROK2 / PROKR2 or SOX10 )(65,136,164,180,199-201).  
(iii) Finally, in some countries, patients with mild, non-syndromic forms of CHH are more likely to be 
treated with contraceptives or hormone replacement therapy (HRT) by their general practitioner or 
gynecologist rather than receiving a complete work-up and accurate diagnosis.  
5.  Diagnosis of CHH 
5.1  Clinical diagnosis 
5.1.1  Minipuberty 
Minipuberty provides a brief window of opportunity to diagnose CHH. For male infants, 
micropenis with or without cryptorchidism can be suggestive of CHH. In such cases, 
hormone testing at 4–12 weeks of life may be used to assist in the diagnosis (60,136,202-
207).  
Typically, low serum testosterone, LH and FSH levels are reported (Table 3) based on 
comparisons with established reference ranges (43,208). However, hormonal testing is not 
routinely prescribed for male infants with micropenis or cryptorchidism. A recent study 
reported the normative reproductive hormonal data from a large group of healthy infants 
(209), which will facilitate the interpretation of hormonal results. Neonates born from one 
CHH parent should undergo hormonal evaluation during minipuberty. The lack of typical 
clinical features in female infants suggesting CHH explains why the diagnosis of neonatal 
CHH is only rarely made in this gender (7,139,205).   
5.1.2  Childhood 
During childhood, the diagnosis of CHH is very challenging as childhood is a physiologically 
hypogonadal period, consistent with the relative quiescence of the GnRH pulse generator.  
5.1.3  Adolescence and early adulthood 
Delayed puberty is the hallmark of CHH diagnosis in adolescence. Patients can exhibit absent 
(TV < 4 ml) or partial puberty (119). Typically, the hormonal profile show hypogonadal T or 
E2 levels and low/normal serum levels of gonadotropins due to GnRH deficiency. However, 
CHH remains a diagnosis of exclusion (see Section 7). Between ages 14-16, CHH is difficult 
to differentiate from CDGP, a common cause of delayed puberty (See section 7.3).  
5.1.4  Evaluation of CHH-associated phenotypes 
It is important to evaluate the presence of CHH-associated phenotypes that may indicate a 
diagnosis of CHH and have significant utility for genetic counselling:  
1. History of cryptorchidism with or without micropenis  
2. Decreased or absent sense of smell, suggesting Kallmann syndrome, is present in approximately half of 
the CHH population and should be evaluated using a standardized olfactory test (158). Formal smell 
testing is especially critical, as 50% of CHH who self-reported a normal sense of smell are in fact 
hyposmic or anosmic by standardized testing (210);  in very young children or in the absence of 
available olfactometry, MRI imaging may be useful as a surrogate for smell testing if it shows olfactory 
bulbs hypoplasia or aplasia (see below) 
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3. Congenital sensori-neural hearing impairment should be systematically evaluated with an audiogram, as 
hearing loss is usually mild or unilateral, and thus patients may be unaware of their deficit 
4. Bimanual synkinesia (mirror movements) 
5. Dental agenesis best assessed by panoramic dental X-ray 
6. Cleft lip and/or palate, and other midline defects 
7. Unilateral renal agenesis or malformation of the urinary tract, both of which should be assessed by renal 
ultrasound 
8. Skeletal anomalies such as scoliosis, polydactyly, clinodactyly, etc 
9. Pigmentation defects 
10. Other stigmata of syndromic forms of CHH, e.g. heart malformation, outer ear anomalies and coloboma 
for CHARGE syndrome, etc (see Table 2) 
5.2  Biochemical testing  
5.2.1  Gonadotropins 
Most men and women with CHH have very low circulating gonadotropin levels (61,123,132), 
and the majority of patients with absent puberty exhibit apulsatile patterns of LH secretion 
(61). Patients with partial puberty can have low-normal circulating gonadotropins levels, 
which is inappropriate in the setting of low sex hormones (T or E2) (131,132) (Figure 3).   
5.2.2  Estradiol 
Females:  
Circulating estradiol levels in CHH women are usually low or in the lower end of the normal 
range during the follicular phase using sensitive assays with a detection threshold of 10 
pg/mL (132,211) (Figure 3). In contrast, the more commonly used immunoassays have poor 
sensitivity, and thus are not accurate in this clinical setting (131,134). Insensitive estradiol 
assays may even result in misdiagnosis or confusion with other causes of anovulation (211).  
Males:  
Although serum estradiol levels are not needed for the clinical diagnosis of CHH, they are 
consistently lower in CHH as compared to normal males using sensitive assays (138,212) and 
could have an impact on bone and metabolic health (213-215). 
5.2.3  Testosterone: 
Males:  
Circulating testosterone levels in CHH patients are usually low, i.e. less than 3 nmol/L (86.5 
ng/dL). This is usually also the case for CHH patients with partial puberty and larger 
testicular volumes (61).  
Females:  
Low circulating androgen levels (androstenedione and testosterone) are reported in women 
with CHH despite normal circulating DHEA sulfate concentrations (132). This relative 
androgen deficiency is likely subsequent to the inadequate stimulation of theca cells by low 
circulating LH. Indeed, serum testosterone levels increase in CHH women during combined 
recombinant LH (rLH) plus recombinant FSH (rFSH) stimulation, whereas T levels do not 
change with rFSH alone (132). 
5.2.4  GnRH test 
Pituitary gonadotropin response to a GnRH challenge test has been specifically evaluated in 
CHH men and women (137). 
Males:  
In CHH men, the LH response is highly variable and correlates with the severity of 
gonadotropin deficiency. However, the latter is already clinically reflected by the degree of 
testicular atrophy, which questions the added value of the GnRH stimulation test 
(135,201,216,217).  
Females:  
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
e 
R
ev
ie
w
s
D
ow
nloaded from
 https://academ
ic.oup.com
/edrv/advance-article-abstract/doi/10.1210/er.2018-00116/5303368 by U
niversity of H
elsinki user on 01 February 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrine Reviews; Copyright 2019  DOI: 10.1210/er.2018-00116 
 
 
13
Pituitary gonadotrope response to the GnRH test has only been evaluated in a few case 
reports (137,139). In most GnRH deficient women, the peak LH response to GnRH 
stimulation was blunted relative to normal women (137).  
5.2.5  Inhibin B   
Males:  
Inhibin B is a hormone secreted by Sertoli cells and reflects Sertoli cell number and function 
(218,219). Inhibin B is under the control of FSH (220,221). Healthy seminiferous tubules 
after puberty also regulate inhibin B production, likely through the control of spermatids 
(222). Most CHH men with absent puberty +/- micropenis and cryptorchidism exhibit low 
serum inhibin B levels (< 30-60 pg/ml), indicating a reduced Sertoli cell population 
(66,123,223). This is consistent with the absence of GnRH-induced FSH stimulation of the 
seminiferous tubules during fetal life and minipuberty (see above, Section 4.2.1.) 
(45,66,217,224). Higher serum inhibin B levels are encountered in a minority of patients with 
absent puberty, but in the majority of patients with partial puberty (61) or acquired 
hypogonadotropic hypogonadism (225), consistent with a robust activation of the HPG axis 
during minipuberty. Serum inhibin B levels correlated well with testicular size (61), and low 
inhibin B levels is a negative predictor of fertility (66). Further, a few studies demonstrated a 
good discrimative value of serum inhibin B to differentiate severe CHH from CDGP (see 
below) (121). 
Females:  
Inihibin B is a marker of the number of antral follicules, and is secreted by the granulosa cells 
(226). Very few studies have investigated circulating inhibin B levels in CHH females (132). 
Low inhibin B concentrations are reported in the range of prepubertal girls (227-229). One 
study demonstrated the critical role of FSH to stimulate ovarian inhibin B secretion as 
evidenced by increased inhibin B levels in response to rFSH alone, but no additional change 
in response to both rFSH and rLH (132).  
5.2.6  Anti-Müllerian Hormone (AMH):  
Males:  
Circulating AMH levels in male CHH patients have been studied during the neonatal period 
and in adulthood (before and after gonadotropin or testosterone treatment) (204,223,230). 
During minipuberty, CHH infants have low AMH, which can be normalized by rFSH and 
rLH treatment (34,204). Untreated CHH adults have high AMH levels when compared to 
normal men, but in the low to normal range of the prepubertal levels in normal boys, 
indicating the immaturity of Sertoli cell population (223). rFSH treatment in previously 
untreated CHH patients induces proliferation of immature Sertoli cells, and thus increases 
AMH levels, while subsequent hCG treatment will increase intratesticular T levels and 
dramatically decreases AMH (223). 
Females:  
Mean serum AMH concentrations are significantly lower in women with CHH than in 
healthy women (Figure 3) (132), although two-thirds of patients display serum AMH levels 
within the normal range. The subgroup of CHH women with the lowest ovarian volume and 
antral follicular count had significantly lower AMH levels consistent with lower FSH levels. 
However, low AMH should not be considered a poor fertility prognosis, as both pulsatile 
GnRH and gonadotropin administration can lead to fertilty and will be accompanied with an 
increase in serum AMH levels.  
5.2.7  Other pituitary hormones 
In the evaluation of CHH, it is important to rule out other pituitary defects by performing an 
exploration of the complete pituitary axis (e.g. to rule out hyperprolactinemia) (231) (See also 
Section 6). A baseline profile including measurments of prolactin, free T4, TSH, morning 
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cortisol and IGF1 should be performed and growth curve should be analysed. In case of 
suspected pituitary insufficiency, appropriate dynamic challenge tests and diencephalic 
imaging should be performed (231). 
5.3  Radiological examination 
Pelvic ultrasound 
Studies on uterine morphologies in CHH women are limited (131,132,232). Pelvic or 
transvaginal ultrasound (when appropriate) demonstrated a significant reduction in mean 
ovarian volume (OV) compared to healthy adult women of a similar age (131-133,232). OV 
correlates with the severity of estradiol deficiency (232) and endometrial atrophy (233). 
Notably, the decrease in OV is greater in KS than in normosmic CHH with a trend towards 
lower serum gonadotropin levels in KS, suggesting a more severe GnRH deficiency (131). 
The only  study that quantified the number of ovarian antral follicles (AF) showed a 
significant decrease in the average number of AF compared to normal, age-matched women, 
consistent with the low levels of AMH (132). Thus, a combined decrease in OV and AF 
count is a phenotypic characteristic of CHH women, and is often mistakenly considered a 
poor fertility prognosis. However, OV and AF respond favorably to gonadotropin stimulation 
in female CHH (see below). 
Testicular ultrasound  
The measurement of testicular size is important to determine the severity of GnRH deficiency 
and track the progress of testicular maturation during fertility treatment. While an 
orchidometer is often used in clinical practice, testicular ultrasound (US) has the advantage to 
assess not only size but also testicular localization. Both methods were equally accurate in the 
hands of an experienced clinician (234,235). As expected, orchidometer overestimates 
testicular volume by approximately 6 cc in comparison to ultrasound, likely due to the 
interference of surrounding soft tissues and has low sensitivity in detecting testicular 
asymmetry (185). Thus, ultrasound has the added benefit during baseline evaluation to 
simultaneously assess testicular size in detail and rule out renal malformations during a single 
evaluation. However, subsequent evaluations can be conducted reliably with an 
orchidometer. 
Brain MRI is performed at baseline to exclude hypothalamic-pituitary lesions, and to 
assess defects in the olfactory bulbs, corpus callosum, semicircular canals, cerebellum 
(207,236) and midline (237). KS patients will typically exhibit unilateral or bilateral olfactory 
bulb agenesis, olfactory tract agenesis and/or gyrus malformation associated with their 
anosmia/hyposmia (238). However, a few KS patients have normal olfactory structures 
despite clinically confirmed anosmia. In this minority of patients, it seems useful to search for 
other causes of congenital or acquired anosmia (i.e. viral infections, trauma etc.). Further, an 
anomaly of the semicircular canals is an important finding, as it suggests the diagnosis of 
CHARGE syndrome (239). 
Bone density and microarchitecture:  
CHH work-up should include the measurement of bone mass via dual-energy X-ray 
absorptiometry (DXA) to assess bone mineral density (BMD) (7). Bone quality can be 
evaluated by processing a trabecular bone score (TBS) or by performing a high-resolution 
peripheral quantitative computed tomorgraphy (HR-pQCT). The latter provides a more 
detailed assessment of bone microarchitecture at peripheral sites (e.g. distal radius, tibia) 
(240). On the other hand, TBS is a textural index that evaluates pixel grey-level variations in 
the lumbar spine DXA image, providing an indirect index of trabecular microarchitecture, 
readily available from the DXA scan (241). Bone work-up should be done at baseline and 
repeated at least two years after HRT to assess the beneficial effect of sex steroids on bone 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
e 
R
ev
ie
w
s
D
ow
nloaded from
 https://academ
ic.oup.com
/edrv/advance-article-abstract/doi/10.1210/er.2018-00116/5303368 by U
niversity of H
elsinki user on 01 February 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrine Reviews; Copyright 2019  DOI: 10.1210/er.2018-00116 
 
 
15
mass and guide subsequent monitoring. The use of FRAX, a clinical algorithm for assessment 
of fracture risk, has not been validated in this particular population (242).  
5.4  Other tests  
5.4.1  Olfaction 
Olfactory function represents a hallmark in the clinical assessment of CHH, as approximately 
50% of patients have a defect in the sense of smell (Kallmann syndrome, also known as 
“olfacto-genital dysplasia”) (243). Olfactory function is assessed using semi-quantitative 
methods such as the UPSIT score (210) or the Sniffin’ Sticks (244,245) tests which gives 
age- and gender-matched scores relative to a reference population. Alternatively, volatile-
stimulated chemosensory evoked potentials can be used (246), although less practical in a 
clinical setting. Partial or subtle olfactory impairment may be seen in some patients (i.e. 
hyposmia or microsmia) raising the question of a continuum rather than a binary 
classification (210,247). While a self-report of anosmia is sensitive and specific, the self-
reporting of a normal sense of smell is unreliable (210). Therefore, formal smell testing 
should be pursued for all CHH patients. 
5.4.2 Hearing 
The prevalence of hearing loss in CHH is reported to be between 5-15% (Table 1). 
Nevertheless, there are no large studies with systematic evaluations of hearing in CHH 
patients, as an audiogram is seldom performed during baseline evaluation. Hearing defects 
range from unilateral, mild hearing loss to complete bilateral sensorineural deafness, however 
conductive hearing loss is seldom encountered (158). Notably, the association of CHH with 
hearing loss points to mutations in specific genes (e.g. CHD7, SOX10, IL17RD) (7,160).  
5.4.3 Spermiogram  
Spermiogram is defined as the quantitative and qualitative analysis of semen in order to 
assess male fertility potential (248). Among the primary parameters, ejaculate volume (which 
is testosterone dependent) as well as sperm motility and morphology are the most critical.  
The latest World Helath Organization (WHO) criteria for interpretation of semen analysis 
were published in 2010 (249) based on semen samples from over 4500 men in 14 countries 
and defined the lower reference limits for the following parameters: 1.5 ml for semen 
volume, 15 million per ml for sperm count, 40% for total motility and 4% for normal 
morphology. Most CHH patients at baseline (particularly those with severe hypogonadism) 
exhibit severe erectile dysfunction and an absence of ejaculate, rendering a spermiogram 
impossible. However, with fertility treatment the majority of CHH males will develop sperm 
in their ejaculate. Interestingly, the concentration of sperm needed for fertilization in CHH 
patients is much lower compared to the WHO guidelines (250). In conclusion, spermiogram 
is indicated at baseline (when possible) and serially after the initiation of fertility treatment. 
6. Genetics of CHH   
6.1 Genetic determinants of pubertal timing     
The timing of puberty varies widely in the general population and is influenced by genetic, 
environmental, and epigenetic factors (3). The studies of pubertal timing in families and 
twins provide evidence that 50–80% of this variation is caused by genetic factors (3-5). 
Recent genome-wide association studies (GWAS) in large populations shed light on the 
genetic determinants underlying the heritability of pubertal timing. By studying ~370,000 
women of European ancestry, Day et al. reported ~400 independent loci robustly associated 
with the age at menarche (251). The individual effect size of each locus ranges from 1 week 
to 1 year, however the cumulative effect of all identified genetic signals only explains 7.4% 
of population variance in age at menarche. Similar results are seen in GWAS on pubertal 
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timing in males using age at voice breaking as a proxy for pubertal timing. A large number of 
the identified loci are implicated in BMI, height and epigenetic regulation consistent with the 
critical links between energy balance, growth and development, and reproduction. Further, a 
subset of loci implicated in the timing of puberty are located in imprinted regions (e.g. 
MKRN3 and DLK1) which exhibit significant effects when paternally inherited (251). 
Notably, a few menarche loci are enriched in or near genes that underlie CHH (e.g. FGF8, 
GNRH1, KAL1, KISS1, NR0B1, TACR3, etc.) or central precocious puberty (MKRN3). In 
conclusion, pubertal timing is a highly polygenic trait, likely involving many individual 
genetic loci. Further studies on larger cohorts with well-studied phenotypes are needed to 
uncover genetic players and determine the contribution of gene-environmental interactions.   
6.2  Genetics of CHH 
Several recent reviews have focused exclusively on the genetics of CHH including the review 
by Stamou et al. in this journal (194,252). Over the last year, four additional genes have been 
reported to underly CHH: KLB (253), SMCHD1 (254), DCC, and its ligand NTN1 (255)   
Herein, we summarize the complexity of CHH genetics.  
Since the first description of "The Genetic Aspects of Primary Eunuchoidism" by Dr 
Franz Kallmann, in 1944 (256), the genetic complexity of the disease has unfolded. Mirroring 
the clinical heterogeneity of CHH, genetic heterogenity also prevails, with mutations in more 
than 30 genes identified to date. These genes have been critical in unraveling the complex 
ontogeny of GnRH neurons: (i) defects in GnRH fate specification; (ii) defects in GnRH 
neuron migration/olfactory axon guidance; (iii) abnormal neuroendocrine secretion and 
homeostasis; and (iv) gonadotrope defects (Figure 4) (7,140,194,252,257). Yet, more than 
50% of cases remain without an identified genetic cause.  
The genetic complexity of CHH is also reflected in its different modes of inheritance: X-
linked, autosomal dominant, and autosomal recessive (7,140,194,252). Incomplete penetrance 
and variable expressivity is also observed (Figure 5). In addition to the Mendelian modes of 
inheritance, oligogenicity has also been reported in CHH. In 2007, loss-of-function mutations 
in 2 CHH genes acting in concert was described in 2 probands (259). The systematic 
screening of eight CHH genes in 2010 in a large cohort of CHH identified oligogenicity in 
2.5% of probands (260). Subsequent studies screening increasingly more CHH genes 
demonstrated even larger degrees of oligogenicity ranging from 7% (261) to 15% (262). The 
advent of high-throughput sequencing significantly enhances the ability to detect multiple 
rare variants in a patient. However, the assessment of a single variant’s pathogenicity and the 
synergistic effects between variants remains challenging.    
The genetic complexity of CHH is further exemplified by pleiotropic genes that can 
exhibit different roles during development. Indeed, the phenotypic richness found in 
"syndromic CHH" is not always linked to a continguous gene syndrome (e.g. large deletion in 
Xp22.31 in a patients with KS, chondrodysplasia punctata and ichthyosis including ANOS1, 
ARSE, and STS (263). Rather, it may arise from mutations in pleiotropic genes that can 
influence unrelated phenotypic traits.  For example, dominant FGFR1 mutations can cause 
CHH with or without anosmia (180,181), Pfeiffer syndrome (264), holoproencephaly (265), 
Hartsfield syndrome (179), or CHH with split hand foot malformation (207). These diverse 
phenotypes may arise by different mechanisms such as the type of mutations (loss or gain-of-
function, haploinsufficiency, dominant negative), or alternatively, be influenced by modifier 
genes, consistent with an oligogenic model of inheritance. Further, different constellations of 
CHH-associated phenotypes define "CHH syndromes" with both clinical and genetic overlap 
(e.g. mutations in SOX10 causing Waardenburg syndrome (177,266) or KS 
(CHH+anosmia)(164) (Table 2). Refining these CHH-associated phenotypes greatly 
enhances the diagnostic yield of targeted gene screening. Indeed, while FGFR1 mutations 
occur in approximately 10% of CHH patients, they are present in 87% of patients with both 
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CHH and SHFM (207). Similarly, while SOX10 mutations underlie 4% of KS, SOX10 
mutations are found in 30% of patients with KS and hearing loss (7). These genetic advances 
challenge the traditional phenotypic classification of syndromes. 
7.  Differential diagnosis of CHH  
7.1  Structural causes  
Structural causes affecting the hypothalamic-pituitary axis may lead to acquired 
hypogonadotropic hypogonadism. These causes can be classified into tumors (pituitary 
adenomas, craniopharyngeomas and other central nervous system tumors), irradiation, 
surgery, apoplexy or infiltrative diseases (i.e. haemochromatosis, sarcoidosis and 
histiocytosis). Less commonly, head trauma or subarachnoidal haemorrhage can be 
associated with acquired HH (267-269). Most patients with structural causes have multiple 
pituitary hormone deficiencies in addition to acquired HH (268). In early adolescence, a brain 
MRI is indicated in patients with delayed puberty and hypogonadotropic hypogonadism when 
there is a break in growth spurt, pituitary hormone deficiency (including diabetes insipidus), 
hyperprolactinemia, and when there are symptoms of mass effect (headache, visual 
impairment, or visual field defects). In late adolescence or adulthood, brain MRI is indicated 
in patients with isolated severe hypogonadotropic hypogonadism (T < 5 nmol/L, high 
suspicion of CHH) and in patients with combined pituitary hormone deficiency, 
hyperprolactinemia or symptoms suggestive of a sellar mass (267,268,270).  
7.2  Genetic causes : Combined pituitary hormone deficiency (CPHD) 
CPHD is a rare congenital disorder characterized by impaired production of pituitary 
hormones affecting at least two anterior pituitary hormone lineages with variable clinical 
manifestations. CPHD may manifest as (i) isolated pituitary hormone deficiencies, (ii) a 
component of other syndromes (i.e. septo-optic dysplasia which combines CPHD with 
hypoplasia of the optic nerve or midline defects), or (iii) pituitary stalk interruption syndrome 
with ectopic posterior pituitary gland (271). To differentiate CPHD from CHH, biochemical 
assessment of pituitary function with measurements of IGF1, morning cortisol, TSH, and free 
T4 and prolactin is needed in addition to evaluating specific clinical manifestations of 
selective anterior pituitary hormone deficiency. Even subtle indications of insufficiency for 
one of the pituitary hormones warrants further testing with appropriate dynamic challenge 
tests and brain MRI (231).   
7.3  Transient GnRH deficiency:  constitutional delay of growth and puberty (CDGP) 
During early adolescence, distinguishing CHH from CDGP is extremely challenging, as a 
delay in puberty is a hallmark of both diseases, and hypogonadotropic hypogonadism is 
present in both. While GnRH deficiency is permanent in most cases of CHH, CDGP is a state 
of transient GnRH deficiency where puberty eventually begins and is completed without 
hormonal treatment (6). In addition, CDGP is a common cause of delayed puberty, whereas 
CHH is considerably more rare. Differentiating CHH from CDGP is crucial in order to allow 
an early diagnosis of CHH, avoid delay regarding hormonal replacement, and alleviate the 
psychological burden associated with delayed sexual maturation (7). In addition, from a 
prognostic point of view, to differentiate a transient condition from a chronic disease will 
affect the patient’s quality of life (7). We will review some features that may assist in this 
differential diagnosis, noting that while individual indicators may not provide a definitive 
resolution, a combination of multiple indicators and clinical observation will strengthen 
arguments for or against a particular diagnosis (Figure 6): 
Growth velocity was recently suggested to help differentiate the different etiologies of delayed puberty (6), 
but was subsequently shown to offer no additional diagnostic value in separating between CDGP and 
CHH (121,126). 
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Testicular size may discriminate boys with CHH from those with CDGP. In a retrospective study of 174 
boys with delayed puberty at age 14-15 years, a cut-off of TV 1.1 ml (measured clinically) showed a 
100% sensitivity and 91% specificity to distinguish CHH from CDGP (121). 
The presence of cryptorchidism and/or micropenis strongly argues in favor of CHH, reflecting the 
absence of gonadotropins and sexual hormones during both fetal life and  minipuberty (6,121). In a 
series of 174 boys referred to a tertiary center for evaluation of delayed puberty, cryptorchidism was 
present in 36% boys with CHH and only in 2% of boys with CDGP (126). 
CHH-associated phenotypes argue against a diagnosis of CDGP. Most notably, congenital anosmia (i.e. 
unrelated to facial trauma, surgery or chemical exposure) favors a diagnosis of KS. The presence of 
anosmia or other CHH-associated phenotypes may favor a diagnosis of CHH, but must also be weighed 
against their frequency in the general population (Table 1). 
A positive family history of CDGP cannot rule out CHH, as CHH families are often enriched for family 
members with CDGP (157). Additionally, autosomal dominant inheritance is seen in both CHH and 
CDGP (122).  
Biochemical evaluation: To date, no biochemical marker can fully differentiate CHH from CDGP (272) in 
early adolescence. GnRH test might be useful for identifying severe cases of CHH. Indeed, when 
GnRH stimulated LH response is blunted, CHH is highly probable. A recent study included 19 CHH 
and 181 CDGP and demonstrated a cut-off of GnRH stimulated LH of 4.3 IU/L to detect CHH with a 
sensitivity of 100% and specificity of 75% (121). Inhibin B levels are also a useful diagnostic adjunct, 
with low values (< 60 pmol/ml) suggesting severe GnRH deficiency (121). Nevertheless, some overlap 
exists especially between partial CHH, CDGP and healthy controls (273,274), thereby highlighting the 
need for larger prospective studies. Higher AMH is suggestive for CHH, although the cut-off is not 
clear (274,275). Further, other markers such as INSL3, DHEAS, IGF-1 do not improve accuracy for 
differential diagnosis. 
Genetic testing is a promising prospect, however evidence as to whether CHH and CDGP exhibit common 
or distinct genetic backgrounds remains unclear. Mutations in IGSF10 have been reported in both 
CDGP and CHH families (276). A shared genetic basis is also partly supported by previous work 
identifying putative pathogenic mutations of known CHH genes in 14% of CDGP probands (277), 
which was significantly higher than in controls. Further, meta-analysis of GWAS studies including 
370,000 women on the age of menarche revealed more than 400 loci associated with the timing of 
puberty, several of which overlap with known CHH genes, such as TACR3, GNRHR, etc (251). 
Nevertheless, a recent study using whole exome sequencing in two cohorts of  CHH and CDGP 
probands suggested distinct genetic architectures (262), with CDGP resembling the control population 
in terms of both the frequency of pathogenic variants in known CHH genes and the presence of 
oligogenicity. Confirmation of these results with larger studies is needed and could lead to a broader 
use of genetic testing to complement clinical and biochemical data for the diagnosis of CHH in 
adolescence. 
7.4  Transient GnRH deficiency: functional hypogonadotropic hypogonadism 
Similar to CDGP (see above), functional hypogonadotropic hypogonadism (FHH) is difficult 
to differentiate from CHH. FHH (frequently termed as functional hypothalamic amenorrhea 
[FHA] in females) is a reversible form of GnRH deficiency, often induced by stressors such 
as caloric deficits, psychological distress and/or excessive exercise (278,279). In adolescents, 
the frequency of FHH is rising (3-5% of the population among young woman, (280) and can 
manifest as primary amenorrhea (281), further complicating its distinction from CHH. There 
is a genetic susceptibility in the inhibition of the HPG axis in the presence of predisposing 
factors, and a shared genetic basis of CHH and FHA in women has been described (282).  
For both genders, malnutrition due to an organic disorder such as celiac disease, 
inflammatory bowel disease (e.g. Crohn’s disease, ulcerative colitis) or other chronic 
inflammatory and infectious states should be ruled out as the primary cause underlying a 
patient’s hypogonadotropic hypogonadism before rendering a diagnosis of CHH (7). 
7.5 Opioid-induded hypogonadotropic hypogonadism 
Opioids use is a major cause of  functional/reversible hypogonadotropic hypogonadism in 
males and females (283,284). In the central nervous system, endogenous opioids inhibit 
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pulsatile GnRH release (285) and suppress LH secretion, resulting in low sex steroid 
production and clinical hypogonadism (284,286-288). Opioid misuse and addiction is an 
ongoing and rapidly evolving public health crisis (289). It is therefore likely that the 
prevalence of HH related to the consumption of these drugs will increase and become a 
growing diagnostic issue particularly among adolescents and young people. 
7.6  Hypogonadotropic hypogonadism associated with metabolic defects  
Late-onset hypogonadotropic hypogonadism is associated with metabolic syndrome, obesity 
and/or diabetes. (290). Contrary to CHH, this disorder is characterized by mild GnRH 
deficiency most commonly occuring after puberty (290). The physiopathology of obesity-
related HH is multifactorial and depends on the severity of the underlying metabolic defect 
(291). A decrease of sex hormone-binding globulin (SHBG) is the major factor responsible 
for low T levels in moderately obese men, while severely obese men (BMI > 40 kg/m2) 
exhibit low total and free T and reduced GnRH-induced LH pulsatility (291). Increased 
aromatization of T to E2 in adipose tissue with subsequent enhanced negative feedback, 
insulin resistance and hypothalamic inflammation are thought to be causative factors that 
alter the function of GnRH neurons and/or pituitary gonadotroph cells (292). Notably, with 
the increasing incidence of childhood obesity, obesity-related HH is also on the rise in early 
adolescence, especially in boys, and can be characterized by delayed puberty (293-295).   
7.7 Hypogonadotropic hypogonadism associated with hemochromatosis 
Hemochromatosis is part of the differential diagnosis for CHH as it can often result in 
hypogonadotropic hypogonadism with no additional pituitary deficiencies and often preceeds 
cardiac and hepatic defects (296). Juvenile hemochromatosis (type 2A) can present with 
delayed puberty or permenant hypogonadtropic hypogonadism due to mutations in 
Hemojuvelin (297,298). Hemochromatosis is confirmed by serum measurement of iron, 
ferritin and transferrin saturation coefficient and molecular diagnosis (299). Family history of 
hemochromatosis also points towards this etiology. It is important not to miss the diagnosis 
hemochromatosis, as a reversal of the associated hypogonadotropic hypogonadism may occur 
after repeated phlebotomy (300).  
8.  Treatment of CHH  
With appropriate hormonal replacement therapy, CHH patients can develop secondary sexual 
characteristics, maintain normal sex hormone levels and a healthy sexual life, and achieve 
fertility. Several regimens of treatment with different administrative routes exist. The choice 
of treatment depends on the therapeutic goal, the timing of treatment, and the personal 
preference of each patient. It is important to know that randomized controlled trials on 
hormonal treatment in CHH are scarce, and data on clinical observational studies are also 
limited. There is no uniform treatment regimen used internationally. The advantages and 
disadvantages of available treatment regimens are summarized in (6,301) Table 4 & 5. 
8.1 Neonatal treatment of CHH  
To date, hormonal therapy during the neonatal period is only applied in male patients 
exhibiting micropenis/cryptorchidism and hypogonadotropic hypogonadism 
(34,136,203,204,206,303). An equivalent therapy is not proposed in female patients, as the 
consequences of severe GnRH deficiency during late fetal period and minipuberty in females 
is unclear.  
In male infants with severe GnRH deficiency, the main goals of hormonal treatment are 
to increase the penile size and to stimulate testicular growth. Early reports in 1999 and in 
2000 have described the benefit of early androgen therapy in boys with either CHH or CPHD 
(202,303). Testosterone treatment can increase penile size and stimulate scrotal development.  
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hCG therapy with or without combination of nasal spray of GnRH has been shown to be 
effective to treat cryptorchidism in neonates and prepubertal boys (304,305). This finding 
could represent a further benefit of neonatal treatment of children with CHH, as 
cryptorchidism is a factor of poor prognosis for adult fertility and is also a risk factor for 
testicular malignancy. On the other hand, orchidopexy —surgery to move an undescended 
testicle into the scrotum—is the current treatment of choice of cryptorchidism. Some 
publications point to a deleterious effect of isolated hCG therapy in boys with cryptorchidism 
(306). A concern for high dose of hCG treatment is its potentially deleterious effect on germ 
cells with increased apoptosis, and thus negative consequences for future fertility (306). 
However, the deleterious effect of hCG has not been demonstrated in CHH males with 
cryptorchidism.  
In 2002, Main et al. reported the effect of subcutaneous injections of rLH and rFSH 
during the first year of life in a CHH infant born with micropenis (203). This treatment led to 
an increase in penile length (1.6 to 2.4 cm), and a 170% increase in testicular volume 
accompanied by an increase in inhibin B levels. Similarly, Bougnères et al. reported the use 
of gonadotropin infusion in two neonates—one diagnosed with CHH and the other with 
CPHD (204). In this study, rLH and rFSH were administrated subcutaneously via a pump for 
6 months. This treatment not only corrected the micropenis in both patients (8 to 30 mm and 
12 to 48 mm, respectively), but also induced testicular growth (0.57 to 2.1 ml and 0.45 to 2.1 
ml, respectively). Serum LH and FSH levels increased to normal or supranormal levels, 
leading to an endogenous secretion of T, inhibin B and AMH. Similarly, Sarfati et al. 
reported another case with a perinatal diagnosis of KS based on presence of an ANOS1 
(KAL1) mutation, the detection of renal agenesis during fetal life, and the presence of 
micropenis at birth (136). The combined gonadotropins infusion from 1 to 7 months of age 
induced the normalization of testicular size (0.33 to 2.3 ml) and penis length (15 to 38 mm). 
Recently, Lambert & Bougneres reported the effect of combined rLH and rFSH injections in 
a series of eight male infants with either CHH or CPHD (206). All patients presented with 
either cryptorchidism or high scrotal testis at diagnosis, and were treated with gonadotropin 
infusion. Apart from the increase in both penile length and testicular size, the authors 
observed complete testicular descent in 6 out of 8 cases. However, the effect of combined 
gonadotropin treatment on cryptorchidism in CHH infants will need to be formally assessed 
by randomized controlled trials. Further, the effect of such treatment on cryptorchid males 
without hypogonadism remains unknown.  
Collectively, these studies suggest that combined gonadotropin therapy in male CHH 
patients during the neonatal period can have a beneficial effect on both testicular endocrine 
function and genital development. This treatment may be superior to androgen therapy, as it 
stimulates Sertoli cell proliferation and the growth of seminiferous tubules, as evidenced by 
the marked increase in TV and in serum inhibin B concentrations (34).  
It is possible that the normalization of penis size in the neonate will lead to a normal adult 
penis size during subsequent pubertal virilization with exogenous testosterone or hCG, thus 
preventing the feeling of inadequacy often reported by CHH males with micropenis (147). In 
parallel, the increase in testicular size, which correlates with the increase in Sertoli cell mass, 
could lead to better outcomes in terms of sperm output during fertility induction in 
adolescence or adulthood (34). Taken together, these data imply that combined gonadotropin 
therapy in males during the neonate period may attenuate the psychological effects of 
micropenis later in adolescence, and potentially improve fertility in adulthood. Thus, 
randomized-controlled trials with larger number of patients are needed to rigorously assess 
the effect of gonadotropins on cryptorchidism in male neonates.  Further, longitudinal studies 
are warranted to determine the long-term benefits on reproductive function of hormonal 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
e 
R
ev
ie
w
s
D
ow
nloaded from
 https://academ
ic.oup.com
/edrv/advance-article-abstract/doi/10.1210/er.2018-00116/5303368 by U
niversity of H
elsinki user on 01 February 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrine Reviews; Copyright 2019  DOI: 10.1210/er.2018-00116 
 
 
21
intervention during infancy. However, there is no data to support such a treatment in female 
CHH patients.  
8.2 Pubertal induction  
8.2.1 Induction of female secondary sexual characteristics  
The literature focusing on the induction of puberty in teenagers (and adult women) with CHH 
is limited. However, the therapeutic objectives are well-defined (7,301,307): to achieve breast 
development; to ensure external and internal genital organ maturity and other aspects of 
feminine appearance, and to promote psychosexual development with respect to emotional 
life and sexuality (149). In addition, puberty induction also increases uterine size, which is 
important for future pregnancy. Finally, optimizing growth in order to achieve a final height 
close to the predicted parental mean target is important, along with acquiring normal bone 
mineral density (301,308). 
Most therapeutic regimens inducing feminization in CHH are not evidenced-based. 
Instead, they arise from expert opinions (7,301,309-311) partly due to the paucity of patients 
(308,311-314). Further, regimens have often mirrored Turner syndrome treatment (315). 
Thus, a dogmatic attitude is to be avoided. We propose that the choice of treatment integrates 
the patient’s opinion, while maintaining a favorable risk-benefit balance.  
In practice, estradiol therapy (oral or transdermal) induces feminization, however 
available protocols vary widely (312,313). As transdermal estrogen in adulthood is associated 
with a good efficacy profile and reduced cardiovascular events, it is reasonable to prioritize 
this formulation for pubertal induction (308). In addition, a recent randomized trial in a small 
number of hypogonadal girls have shown that transdermal estradiol resulted in higher 
estradiol levels and more effective feminization compared to oral conjugated equine estrogen 
(314). 
Transdermal estradiol administration is often started at low doses (for instance 0.05–0.07 
µg/kg nocturnally, from 11 years), with the goal of mimicking estradiol levels during early 
puberty. In older CHH girls when breast development is a priority, transdermal estradiol is 
started at 0.08–0.12 µg/kg (301,308,316). The estradiol dosage should then be increased 
gradually over 12–24 months. After maximizing breast development and/or after the break-
through bleeding, cyclic progestagen is added. In the majority of CHH females, 
estroprogestin therapy is effective to induce harmonious development of the breasts and 
genitals. In turn, the restoration of normal secondary sex characteristics likely contributes to a 
more satisfactory emotional and sexual life (149). Estrogen treatment also increases uterine 
size (133), and estroprogestin therapy induces monthly withdrawal bleeding. However, this 
treatment does not restore ovulation. Finally, estrogen therapy induces a growth spurt and 
increases bone density in the majority of CHH female adolescent and older women (317). 
The treatment options are summarized in Table 4. 
8.2.2 Induction of male secondary sexual characteristics 
Therapeutic goals in the adolescent CHH male are also well defined: to induce virilization; to 
reach optimal adult height; to acquire normal bone mass and body composition; to achieve 
normal psychosocial development; and to gain fertility. However, available treatment 
regimens may not always cover all of these aspects. The hormonal treatment options for the 
induction of puberty in male CHH are presented in Table 5. 
As with CHH girls, there is a paucity of literature and a lack of randomized studies 
comparing different treatment modalities, with only one randomized study including several 
CHH patients (318). Difficulties also arise from studies aggregating heterogeneous cohorts of 
CHH patients in terms of clinical presentation (i.e. degree of spontaneous puberty) and 
genetics.  
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Early treatment is crucial and usually involves an injectable testosterone ester such as 
testosterone enanthate (123,301,319). Pediatric endocrinologists treating younger patients 
(from 12 years of age) typically begin treatment with low-dose testosterone (for example, 50 
mg of testosterone enanthate monthly) and gradually increase to full adult dose (250 mg 
every 2-4 weeks) over the course of approximately 24 months. For CHH patients seeking 
treatment in later adolescence or early adulthood, a higher dose of testosterone can be used to 
induce rapid virilization. Initial testosterone doses (such as 100 mg testosterone enanthate 
monthly) can be quickly increased to 250 mg IM monthly. Such regimens induce secondary 
sexual characteristics and maximize final height (301,320). Side effects for T treatment 
include erythrocytosis, premature closure of the epiphysis (if doses are too high during the 
first year of treatment), and occasional pain and erythema at the injection site. Of note, 
testosterone treatment does not stimulate testicular growth or spermatogenesis (123,319), 
since intragonadal T production is needed to stimulate spermatogenesis. In contrast, increased 
testicular growth during testosterone treatment indicates CHH reversal and requires treatment 
withdrawal followed by hormone profiling (152).  
Induction of testicular maturation  
Gonadotropins are used for fertility treatments in adult CHH patients, but can also be used to 
induce pubertal maturation in adolescent CHH males. An additional advantage of 
gonadotropin treatment compared to testosterone treatment is the stimulation of testicular 
growth and spermatogenesis. Therefore, gonadotropin treatment may offer important 
psychological reassurance in adolescents and enhance self-confidence. Varying treatment 
protocols including hCG alone or in combination with FSH have been used to induce puberty 
in boys (321-325). In a retrospective analysis of CHH boys, Bistrizer et al. showed a 
comparable virilizing effect of monthly testosterone injections and weekly hCG injections 
(5000 IU/week), but testicular growth was significantly larger in boys treated with hCG 
(321).  
Rohayem et al. studied a relatively large group of adolescents with delayed puberty, most 
of them with absent puberty (n = 34) (325). The adolescents received low dose hCG (250-500 
IU twice weekly) with increasing increments of 250-500 IU every 6 months, and rFSH was 
added once serum T achieved targeted pubertal level (5.2 nmol/L). This treatment led to a 
substantial increase in TV (bi-testicular volumes: 5 ± 5 to 34 ± 3 ml) and induction of 
spermatogenesis in 91% of patients (325). 
Pretreatment with FSH in adolescents with severe GnRH deficiency 
The rationale behind priming with FSH alone in patients with severe GnRH deficient is that 
the mass of Sertoli cells is a predictor of future sperm output. FSH induces proliferation of 
immature Sertoli cells prior to seminiferous tubules maturation in rats (326), Macaca mulatta 
(327), and probably also in humans (328). Conversely, adult men with biallelic inactivating 
FSHR mutations exhibit small testicular size and variable degrees of spermatogenesis failure 
(329). In addition, it has been suggested that CHH patients with absent puberty +/- 
micropenis and cryptorchidism likely have a suboptimal Sertoli cell complement due to lack 
of minipuberty as evidenced by low serum inhibin B levels, and could thus benefit from pre-
treatment with FSH. A study of 14 gonadotropin-deficient boys treated with rFSH priming 
showed significant increases in inhibin B and TV in the absence of an increase in 
intragonadal T production consistent with proliferation of Sertoli cells (330). 
Spermatogenesis was achieved in 6 out of 7 boys who provided semen samples, with a 
maximal sperm count ranging from 2.9 to 92 million/ml (median 8.5 million/ml) (330).  A 
subsequent randomized controlled study (see below) showed similar results in young adults 
(331). Thus, pretreatment with FSH prior to testicular maturation appears to compensate for 
the suboptimal Sertoli cell proliferation during late fetal life and minipuberty, and thus might 
be beneficial in adolescent males for future fertility. However, this treatment is intensive, 
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requires frequent injections and close follow-up, and might not be optimal for all adolescent 
CHH patients. A large multicenter study to evaluate the benefits and cost-effectiveness of 
pre-treatment with FSH in severe cases of adolescent and adult CHH is warranted.   
8.3 Hypogonadism treatment in adults 
8.3.1 Females 
Hormonal treatment is required in adult CHH females for maintaining bone health, increasing 
the feminine appearance, improving emotional and sexual life, and promoting general well-
being. Studies on hormonal treatment in adult CHH patients are limited and several centers 
favor estro-progestin (E-P) replacement therapy instead of oral contraceptive pills (OCP). 
Indeed, the effect of ethinylestradiol on bone health of hypogonadal women is less 
established than the effect of 17β-estradiol. Additionally, long-term E-P replacement 
preserves BMD in another population of young hypogonadal women with Turner syndrome 
(332). More recently, a 2-year randomized trial comparing HRT versus OCP in hypogonadal 
women with primary ovarian insufficiency revealed significantly higher BMD of the lumbar 
spine in the HRT group (333). In addition, there has been no report of increased risk for 
thromboembolic events in CHH females on E-P substitution. Estradiol can be given either 
orally (at a dose of 1–2 mg) or transdermally (50 µg daily by patch or 2 pumps of 0.06% gel 
daily) with a cyclic progestin regimen (i.e. micronized progesterone 200 mg or 
dydrogesterone 10 mg, daily during the last 14 days of the cycle) to avoid endometrial 
hyperplasia. E-P treatment induces monthly withdrawal bleeding but does not restore 
ovulation.  This treatment should be maintained at least until the natural age of menopause.  
8.3.2 Males 
Long-term androgen treatment is required in male CHH patients to maintain normal serum T 
levels, libido, sexual function, bone density and general well-being. The different regimens of 
T replacement therapy are summarized in Table 5.  
Testosterone can be given as an injectable formulation (aromatizable androgen such as 
enanthate, cypionate or undecanoate) or transdermal application (123,319,334). The 
maintenance dose of testosterone is usually 250 mg of T enanthate IM every 2-4 weeks, 1g of 
T undecanoate IM every 3-4 months, or 50-80 mg of testosterone gel daily (Table 5). The 
surveillance of trough serum T levels is important, as there exists considerable variation 
regarding the metabolism of exogenous testosterone products among CHH patients (154). For 
testosterone injections, the frequency of injections should be assessed according to the trough 
serum testosterone measurement, targeting the lower end of normal range. Intra-muscular T 
injections may cause significant differences between the peak and trough T levels. Pilot 
studies have shown that weekly subcutaneous injection of low doses of T cypionate or T 
enanthate can induce a more steady profile of plasma T (335),(302).  For patients treated with 
testosterone gel, the target for random serum T level is the middle of normal range. The 
advantage of T gel is its pharmacokinetics with a more stable T concentration within the 
normal adult range, and the lack of minimally invasive injections. However, patients on T gel 
should avoid skin contact with others (partners or children) as there are known risks for 
hyperandrogenism in women (336) or for precocious puberty in children (337). Among the 
reported disadvantages of transdermal testosterone are the high cost and the lack of 
reimbursement in some countries. Whichever treatment is used, CHH men are challenged to 
adhere to long-term treatment and poor adherence may contribute to adverse effects on bone, 
sexual and psychological health (146). 
8.4  Fertility treatment  
8.4.1  Induction of fertility in females CHH  
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Infertility in women with CHH is caused by impaired pituitary secretion of both 
gonadotropins, LH and FSH, leading to an impaired ovarian stimulation. Specifically, GnRH 
deficiency leads to an impairment in follicular terminal growth and maturation resulting in 
chronic anovulation. However, there is no evidence of a decreased follicular reserve (132). 
This point must be emphasized to patients and their families as soon as the diagnosis is made. 
Indeed, the combination of small ovaries, decreased antral follicular count, and low 
circulating AMH concentrations observed in women with CHH could wrongly suggest an 
alteration in ovarian reserve and a poor fertility prognosis (132). In contrast, these patients 
should be informed that ovulation induction will lead to a fairly good outcome in terms of 
fertility in the absence of a male factor of infertility or significantly advanced age (> 35 
years) (132,133,338-340).  
Before considering ovulation induction, sono-hysterosalpingography or traditional 
hysterosalpingography could be performed in order to evaluate both the integrity and the 
permeability of the uterine cavity and fallopian tubes (341). Alternatively, sono-
hysterosalpingography could be performed after a couple of cycles of successful ovulation in 
the absence of pregnancy. In addition, an associated male infertility factor should be ruled out 
by obtaining a semen analysis (340). Couples should be advised on the optimal timing of 
sexual intercourse during the ovulation induction, as this first-line therapy does not require in 
vitro fertilization (132,133,338,339). 
The goal of ovulation induction therapy in female patients with CHH is to obtain a mono-
ovulation to avoid multiple pregnancies. Ovulation can be achieved either with pulsatile 
GnRH therapy or stimulation with gonadotropins. The latter includes either extractive or 
rFSH treatment followed by hCG or rLH to trigger ovulation (342). The therapeutic choice 
will depend on the expertise of each center and the local availability of the different medical 
therapeutics.  
Pulsatile GnRH treatment  
Pulsatile GnRH therapy via a pump was first proposed by Leyendecker et al. to induce 
ovulation in women with different causes of hypogonadotropic amenorrhea (WHO I, 
anovulation) (343-345). Given its remarkable efficiency in acquired forms of HH, pulsatile 
GnRH was successfully applied to CHH women (346) and other causes of acquired HH (347-
349). Both subcutaneous and intravenous routes for GnRH administration are appropriate to 
restore fertility (347,350). Pulsatile GnRH restores the physiological secretion of pituitary 
gonadotropins, which in turn induces ovulation in CHH patients (351-355). The major 
advantage of pulsatile GnRH therapy compared to gonadotropin treatment is the decreased 
risk of multiple pregnancy or ovarian hyperstimulation (347,348,355). Consequently, it 
requires less monitoring and surveillance during treatment. Therefore, if pulsatile GnRH 
treatment is available within the region the patient is being treated, it should be considered 
the first-line of therapy in CHH females, given that it is the most physiological regimen and 
results in fewer side effects.    
Physiologically, GnRH pulse intervals vary throughout the menstrual cycle, as evidenced 
by LH pulse studies in a large series of women with regular menses (356). Based on this 
study, the frequency of GnRH pulses is set for every 90 minutes during the early follicular 
phase of treatment, and subsequently accelerated to every 60 minutes during the mid and late 
follicular phase. After ovulation, the frequency is reduced to every 90 minutes. Finally, 
during the late luteal phase, there is a further decrease to every 4 hours that will favor FSH 
secretion over LH. However, pulsatile GnRH at a constant frequency of 90 minutes also 
induces maturation of ovarian follicles, an LH surge and ovulation (350).  
The dosage of GnRH required to restore normal ovulation has been well studied in 
females with CHH or functional hypothalamic amenorrhea. Intravenous doses of 75 ng per kg 
per pulse are considered a physiological dose to induce adequate pituitary gonadotropin 
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secretion and ovarian stimulation (357). In 30% of CHH females, pituitary resistance is 
present at the first cycle, requiring increased GnRH doses and longer stimulation (354). Once 
ovulation is achieved, the corpus luteum must be stimulated to produce progesterone, which 
is mandatory for embryo implantation. The pulsatile GnRH pump is able to maintain 
endogenous pulsatile LH secretion sufficient to ensure progesterone release by the corpus 
luteum until the endogenous secretion of hCG from the placenta begins (355,358). Another 
treatment option for luteal support is hCG (subcutaneous injections of 1500 IU every 3 days 
for 3 times) which is less costly and well tolerated. The success rate of ovulation induction is 
excellent in CHH females, reaching 90% ovulation per cycle, and 27.6% conception per 
ovulatory cycle. The number of cycles needed to obtain a pregnancy is quite variable, ranging 
from one to six cycles (350,355). The multiple pregnancy rate is slightly higher than the 
general population at 5-8% (357), but much lower than with gonadotropin therapy. Notably, 
pulsatile GnRH pump can be effective even in the presence of GnRH resistance, such as in 
women with CHH who harbor partial loss-of-function mutations in GNRHR (351,354). 
When administered subcutaneously, higher doses (15 µg per pulse) are needed, and 
typically the frequency of pulses are kept at one every 90 minutes. The success rate is slightly 
lower at 70% of ovulation rate per cycle (359). However, the subcutaneous administration 
has no risk of phlebitis, and is more convenient. 
GnRH pulse treatment is discontinued when pregnancy occurs, and adverse effects in 
early pregnancy have not been reported (360). After several unsuccessful cycles of GnRH 
stimulation, gonadotropin therapy should be proposed (see below) (338,339) to bypass a 
potential pituitary resistance associated or not with loss-of-function GNRHR mutations. 
(197,354).  
Gonadotropin treatment 
In CHH women, ovulation can also be achieved with FSH treatment followed by hCG or rLH 
to trigger ovulation. However, women with severe GnRH deficiency have very low 
gonadotropin levels, thus requiring both FSH and LH during the follicular phase. LH 
stimulates the ovarian theca cells to produce androgen substrates allowing sufficient secretion 
of estradiol by the maturing follicles (132,233,338,361). Estradiol is necessary for optimal 
endometrial thickness and cervical mucus production, which in turn are needed for sperm 
transit and embryo implantation (132). Typically, subcutaneous hMG (human menopausal 
gonadotropins, FSH + hCG) doses of 75–150 IU per day are sufficient to induce ovulation. 
Usually, a dominant follicle (>18 mm) will mature in approximately 12 days. The starting 
dose of hMG is often increased or decreased depending on the ovarian response, as assessed 
by repeated serum estradiol measurements or by using ultrasonography to count and measure 
maturing follicles every other day. This regimen minimizes the risk of multiple pregnancies 
and ovarian hyperstimulation syndrome. After ovulation, progesterone production can be 
stimulated by repeated hCG injections, or direct administration of progesterone during the 
post-ovulatory phase until the end of the luteal phase. 
In vitro fertilization 
If conception fails after repeated successful ovulation induction in CHH females, in vitro 
fertilization may be an alternative (362,363). 
8.4.2. Induction of fertility in CHH males 
CHH is one of the few medically treatable causes of male infertility, and fertility treatments 
have very good outcomes. Fertility induction can be accomplished either by long-term 
pulsatile GnRH therapy or with combined gonadotropin therapy.  
Pulsatile GnRH treatment  
Pulsatile GnRH treatment is a logical approach in patients with CHH seeking fertility. 
Physiological GnRH secretion is episodic, and therefore GnRH treatment requires 
intravenous or subcutaneous GnRH administration in a pulsatile manner via mini-infusion 
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pump (364). This therapy will stimulate pituitary gonadotropin secretion and in turn 
intragonadal testosterone production, resulting in the initiation and maintenance of 
spermatogenesis as evidenced by increased testicular volume and sperm output by 12 months 
of treatment on average. The common initial dose is 25 ng/kg per pulse every 2 hours, with a 
subsequent titration to normalize serum testosterone to the adult normal range (66,365-367). 
Response to treatment varies according to the degree of GnRH deficiency, with normalization 
of TV and successful induction of spermatogenesis for all patients with partial puberty. On 
the contrary, TV and sperm counts are lower in patients with absent puberty and 20 % of 
these patients remained azoospermic despite 12-24 months of pulsatile GnRH treatment (66). 
A systematic literature review on this issue is listed in Table 6.  
Gonadotropin treatment 
Gonadotropin treatment (hCG alone or combined with rFSH) is another treatment option for 
fertility induction in male CHH patients. While intramuscular (IM) injections were prescribed 
in the past, subcutaneous gonadotropin injections are currently preferred, and various 
formulations are used. Typical doses vary from 500 to 2,500 UI 2-3 times a week for hCG, 
and from 75 UI to 225 UI 2-3 times a week for FSH preparations, namely hMG, highly 
purified urinary FSH (uFSH) or recombinant FSH (rFSH).  The dosage of hCG is adjusted 
based on trough serum T, and rFSH dosage is titrated based on serum FSH levels and sperm 
counts. 
Fertility outcomes in CHH men 
From the early 1970s to 2017, a series of forty papers were published that address fertility 
and spermatogenesis in CHH patients, and included more than one thousand CHH patients 
(Table 6). More than 80% of the patients have been treated by combined gonadotropin 
therapy.  Although the GnRH pump is an effective therapy to induce spermatogenesis in the 
absence of pituitary defect, the significant use of gonadotropins may indicate that GnRH 
therapy is not available in several countries, including the US where it has been largely used 
only in a research setting. Further, this therapy is expensive and likely less comfortable than 
gonadotropin injections given the long period (1-3 years) needed to mature the testes.  
Both pulsatile GnRH and gonadotropin therapy are effective to induce spermatogenesis 
and fertility in men with CHH (403-405), however no clear superiority of GnRH versus 
gonadotropins was observed. Similarly, none of the available FSH preparations appear to 
differ in terms of sperm output.  
The overall success rate in term of sperm output is variable across studies (64 to 95% 
success), with sperm counts ranging from zero to several hundred million/ml. The weighted 
average median time to achieve sperm production was slightly over a year (Table 6). It is 
well established that even low sperm concentrations in CHH men are sufficient to impregnate 
partners (250). Pregnancy was successfully achieved in 175 CHH patients’ partners (Table 6), 
and successful pregnancies were reported in 16 to 57% of CHH patients desiring fertility. As 
reported (Table 6), the majority of the pregnancies obtained were by natural conception. In a 
minority, in vitro fertilization was necessary because of the existence of concomitant ovarian 
or utero-tubal abnormalities in the partner (references quoted in Table 6). Conversely, 192 
patients were not able to produce sperm despite long-term gonadotropin treatment (median 24 
months), corresponding to 12-40% depending upon the study. In patients with azoospermia 
after treatment or poor sperm quality, more invasive treatments such as testicular sperm 
extraction were proposed followed by intracytoplasmic spermatozoid injection (ICSI) (390), 
however the outcomes are not clearly outlined in these studies.  
The major limitations of most studies are (i) the often small population size, (ii) the 
inclusion of all types of patients with hypogonadotropic hypogonadism (i.e. severe, partial, or 
AHH, which are known to have different outcome in terms of fertility); (iii) the inclusion or 
exclusion in some studies of cryptorchid men with variable dates of postnatal surgery that 
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could also impact prognosis; (iv) the absence of studies taking into account the genetic 
mutations as a predictor for treatment outcome; and (v) the absence of prospective 
randomized studies comparing head-to-head gonadotropin treatment to pulsatile GnRH 
therapy.  
Despite these limitations, there are some lessons to be learned: (i) sperm counts may 
improve but rarely normalize in CHH patients based on WHO criteria; (ii) low sperm 
concentration does not always preclude fertility in men with CHH; and (iii) several predictive 
factors have been identified in this population: 
Testicular volume. TV is an indicator of the degree of GnRH deficiency and is a positive predictor of 
sperm output (66). When we consider the entire population of CHH treated for infertility (n=994), the 
average testicular size was 3.5 mL at baseline and increased to 8.6 mL by the last visit. However, the 
spectrum of TV at baseline varies widely within and across studies. Thus, it is not surprising that 
studies including patients with milder forms of GnRH deficiency had the best sperm output (Table 6). 
In contrast, studies in which the majority of CHH men exhibited prepubertal testes tended to have the 
poorest results. These patients usually lack the beneficial stimulatory effects of gonadotrope activation 
during the minipuberty and could benefit from a pre-treatment with rFSH prior to GnRH (See below, 
(331)). 
Cryptorchidism. The presence of unilateral or bilateral undescended testes reflects the severity of 
gonadotrope axis deficiency, and is thus one of the main features of antenatal-onset GnRH deficiency. 
Cryptorchidism is recognized as a negative predictor of sperm output, and patients with bilateral 
cryptorchidism have lower sperm counts than those with the unilateral variant or those without 
cryptorchidism. Also, cryptorchid patients require a longer time to attain spermatogenesis (66). Despite 
>1,000 CHH men included in the various studies focusing on spermatogenesis/fertility, only 19% had 
cryptorchidism. Further, in 42% of studies no patients with cryptorchidism were included. 
Furthermore, 30% of studies explicitly excluded cryptorchidism because of an expected poorer 
spermatogenesis prognosis. A number of factors may be involved in the cryptorchidism-related germ 
cell depletion, including apoptosis of germ cells in a testis that remains too long in the abdomen (406). 
In this setting, a surgical correction should be recommended as early as 6 months to 1 year of age 
(407).  
Prior exposure to androgens. A single study considered prior androgen therapy to be associated with a 
poorer prognosis (393), but this result was not reproduced in subsequent studies (66,389,397,408,409). 
Thus, the impact of prior androgen treatment on fertility remains controversial.   
Pretreatment with FSH 
The fertility outcome with GnRH or classical gonadotropin therapy is suboptimal, especially 
in patients with severe GnRH deficiency. In 2013, a randomized study explored the addition 
of rFSH pre-treatment to standard GnRH pulsatile therapy in 13 young adults with severe 
GnRH deficiency (TV < 4 mL) and no prior gonadotropin therapy (331). Patients with 
cryptorchidism were excluded in this study. After 4 months of rFSH alone, mean TV doubled 
from 1 to 2 mL in the absence of increased intragonadal T with a concomitant increase in 
inhibin B levels into the normal range. Further, histological findings demonstrated an 
increase in the diameter of the seminiferous tubules compared to baseline without any sign of 
maturation, as well as enhanced proliferation of immature Sertoli cells and spermatogonia 
(331). Following 2 years of pulsatile GnRH, both groups (with and without rFSH pre-
treatment) normalized serum T levels and exhibited significant testicular growth. All patients 
in the pre-treatment group developed sperm in their ejaculate (versus 4 out of 6 in the GnRH-
only group) and showed trends toward higher maximal sperm counts, testicular volumes and 
serum inhibin B levels, although it did not reach statistical significance mainly due to the 
small sample size. Thus, larger prospective multicenter studies are needed to support the 
superiority of pre-treatment with FSH prior to classical treatment (GnRH or hCG+FSH) on 
improving fertility outcomes in patients with severe GnRH deficiency, with and without 
cryptorchidism and  to assess the cost-effectiveness of pretreatment with FSH.  
8.5  Management of adverse health events related to CHH  
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8.5.1  Bone loss and fracture  
A recent mixed longitudinal study of 2014 healthy children has significantly improved our 
understanding of skeletal development. McCormack et al. showed that (i) at age 7 years, 
healthy children had obtained only 30%-38% of maximal observed whole body mineral 
content (BMC); (ii) during puberty, a significant gain in BMC occurred, (iii)  the mean age at 
peak rate of whole BMC aquisition was 14.0 years in boys, and 12-12.5 years in girls (410) 
which was, on average, 0.6-1.2 years after the peak height velocity, and (iv) another 7% to 
11% of maximal observed BMC was gained after linear growth had ceased (410).  
The relative roles of androgens and estrogens in bone metabolism in bone health was 
recently investigated in adult men. Endogenous sex steroids were suppressed with goserelin 
acetate and the patients were subsequently treated with increasing doses of testosterone only, 
or in combination with aromatase inhibitor anastrozole to suppress conversion of testosterone 
to estradiol (411). The results from this study demonstrated that bone resorption increased 
markedly once estradiol levels were low, even if serum testosterone was substantially 
elevated (411). Estradiol deficiency primarily affected the cortical bone. Cut-offs of <10 
pg/ml for E2 and < 200 ng/dl (6.9 nmol/l) for testosterone (with intact aromatization) were 
suggested undesirable for bone health (411).  
Consistent with these data, low BMD is present in the majority of CHH patients. Yet, 
important variability exists regarding the degree of bone involvement in CHH, as illustrated 
by a recent report of older never-treated CHH patients with low to near-normal BMD and no 
significant difference compared with patients treated by HRT (412). These data suggest that 
the beneficial effect of sex steroid replacement therapy on bone status in this specific 
population may be smaller than previously thought. However, the authors could not 
completely rule out the possibility of occasional hormone treatment in the past in older 
“never treated CHH”. Similarly, they could not exclude the possibility of suboptimal 
adherence to chronic hormone therapy in the "treated" CHH patients.  
Bone remodeling is low in CHH as suggested by the only study that performed iliac crest 
bone biopsies in CHH patients with low bone mass (413). Data on bone remodeling markers 
are inconclusive and do not always correlate with BMD (414). Evidence on fracture 
incidence is scarce, with some reports of incidental vertebral fractures but no comparison of 
the prevalence against controls (414,415).  
HRT is  the first-line treatment for CHH-associated bone loss, with anti-resorptive drugs 
(bisphosphonates, denosumab) as second-line therapeutic choices (416). Given the male 
gender predominance of CHH, the effect of gonadal steroid replacement has been principally 
studied in males receiving testosterone and/or gonadotropins. Testosterone increases BMD in 
CHH (413,417) and mixed hypogonadal cohorts (418-421). Increased levels of bone 
formation markers such as P1NP, usually observed early in the course of treatment, possibly 
reflect the anabolic effects of androgens (422,423). It remains unclear whether testosterone 
replacement fully reverses the bone phenotype (418) or only partially improves BMD (417). 
Age at onset of HRT might be a crucial prognostic factor for the therapeutic response. In the 
first study exploring the link between CHH and bone, Finkelstein et al described bone 
densities measured by computed tomography in 21 CHH men, of whom 15 initially had fused 
epiphyses and 6 had open epiphyses. The majority of patients had received prior androgen 
treatment. After bringing testosterone levels to within the normal range, the younger group 
increased both cortical and trabecular bone densities, whereas those with initially fused 
epiphyses displayed only an increase in cortical bone density (413). The authors hypothesized 
that this difference reflects the physiological bone accretion that occurs during normal sexual 
maturation. These data imply that there is a critical period of skeletal response to sex steroids, 
which would further stress the importance of timely diagnosis of CHH. Nevertheless, another 
study focusing on older CHH patients (median age of 56 years) revealed substantial bone 
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response to testosterone replacement despite delayed diagnosis and onset of HRT (141). 
Therapeutic adherence may also explain the variability observed. Highlighting the 
importance of compliance to HRT, Laitinen et al demonstrated that prolonged cessations in 
HRT (more than 5 years in total) were associated with decreased bone mineral density in the 
lumbar spine, hip, femoral neck and whole body, although no difference was observed in 
fracture prevalence (414). 
It should be noted that some genes involved in CHH may also have direct implications on 
bone health, which may confound the results reported from the small series of CHH men. 
Specific genetic causes that may directly affect bone include mutations in FGF8, FGFR1 and 
SEMA3A (182,424).  
Despite the importance of estrogen for the male skeleton, measurement of estradiol is not 
routinely performed in CHH patients with bone defects. This attitude is based on the fact that 
standard testosterone treatment is aromatizable and corrects low estrogen levels (212). 
However, this should be considered in cases with suboptimal response to HRT and after 
excluding more frequent causes such as inadequate compliance.  
As in other causes of secondary osteoporosis, adequate calcium intake (> 1000 mg/day) 
should be assured. Vitamin D deficiency is prevalent in the CHH population (415) and should 
also be corrected. Targeting levels > 30 µg/l (= 75 nmol/l) is reasonable in the presence of 
low BMD. A small retrospective study suggested that the central hypogonadism as seen in 
CHH might lead to worse bone outcomes as compared to primary hypogonadism 
independently of gonadal steroids levels (425). The authors postulated that severe vitamin D 
deficiency in CHH is due to decreased LH-dependent vitamin D 25-hydroxylation in the 
testes. Nevertheless, no difference in vitamin D levels was detected in a larger cohort of CHH 
patients in comparison with age- and BMI-matched controls (426). Further studies addressing 
this issue should focus on removing the bias of seasonal variation of vitamin D.  
8.5.2  Metabolic defects 
Metabolic defects are present in CHH patients and are commonly thought to be secondary to 
sex steroid deficiency (292,427). The prevalence of overweight and obesity in CHH patients 
is between 40-50% according to a recent nationwide Italian cohort of patients (134), similar 
to the general Italian population (428). However, another study detected increased prevalance 
of metabolic syndrome in CHH in comparison to the general population (429). The latter 
compared 332 young CHH patients without prior androgen treatment versus 395 age- and 
BMI-matched controls and revealed a significantly increased prevalence of all components of 
metabolic syndrome (i.e. waist circumference, arterial blood pressure, fasting glucose, 
HOMA-IR, serum triglyceride levels).  
Testosterone therapy in CHH leads to an improvement in insulin sensitivity (430,431), a 
reduction in high-sensitivity C-reactive protein levels (430) and LDL cholesterol (432), as 
well as  increased lean mass and decreased visceral adiposity (431). Further, short term 
withdrawal of testosterone therapy in male CHH patients causes mild insulin resistance and 
increased fasting glucose levels (427). Similar to testosterone therapy in male CHH patients, 
gonadotropin replacement therapy is accompanied by increased lean mass, reduced body fat 
and waist-to-hip ratio, increased insulin sensitivity and reduced triglycerides levels (433).   
It is possible that genetic determinants predispose certain CHH patients to metabolic 
disturbances. Leptin deficiency or resistance leads to defective signaling of different 
metabolic cues to the hypothalamus which normally regulate both energy homeostasis and 
reproductive capacity (434). Recently, the FGF21/KLB/FGFR1 pathway was also highlighted 
as an important player underlying the link between reproduction and metabolism (253). In 
this study, the majority of CHH probands harboring KLB mutations (9/13) exhibited some 
degree of metabolic defect (i.e. overweight, insulin resistance, and/or dyslipidemia), 
consistent with the potential role of this pathway in metabolic health. 
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9. Conclusions 
Despite a set of relatively straight-forward diagnostic criteria, the phenotypic spectrum of 
CHH is broad. This includes a significant proportion of reversal cases, an overlap with 
common reproductive disorders such as CDGP and FHH, and the presence of CHH as a 
component of more complex entities such as CHARGE and Waardenburg syndromes.   
Timely diagnosis is critical, however the clinical presentation and biochemical profiles are 
often not fully informative in early adolescence as the presentation of CHH closely resembles 
that of CDGP.  One possible opportunity for earlier diagnosis is during minipuberty, but 
currently the importance of evaluating minipuberty is not known. The advance of 
biochemical testing with minimal blood samples (e.g. blood dry-spots) offers the potential to 
assess the HPG axis function in neonates in normal and disease states.   
And finally, the discovery of genes involved in GnRH ontogeny have helped to elucidate 
the pathophysiology as well as improve genetic counseling of the disease, and have assisted 
in rendering an accurate diagnosis. The advent of high-throughput sequencing technologies 
have significantly increased the identification of rare variants. However, this results in a 
specific challenge to classify for pathogenicity, especially in the context of the oligogenicity 
seen in CHH. Large, multi-national studies are required to define CHH genetic risks 
associated with the spectrum of rare variants.  
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Figure 1. Pubertal progression in two male patients with delayed puberty. Testicular 
volume (TV) was plotted on the age-matched puberty normogram. (A) Patient 1 was 
diagnosed with delayed puberty at age 14 (TV 3mL) and completed pubertal development at 
age 18 (TV 16mL) confirming CDGP diagnosis. (B) Patient 2 was diagnosed at age 15 (TV 
3mL) and discharged at age 17 (TV 8mL), despite the fact that his progression is still 
abnormal (< -2SD) using the pubertal nomogram. Thus the differential diagnosis between 
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CDGP and partial CHH is still unclear. Pubertal nomogram obtained courtesy of Dr. Van 
Buuren from http://vps.stefvanbuuren.nl/puberty/. 
Figure 2:  Non-reproductive, non-olfactory signs associated with Kallmann syndrome. 
(A) Coronal CT scan showing the normal palatine bone in a normal subject (yellow circle). 
(B) Cleft palate (yellow arrow) in a patient with Kallmann syndrome carrying a heterozygous 
FGFR1 mutation (adapted from (161). (C) Iris depigmentation of left eye in a patient with 
SOX10 mutation. (D) Oculomotor nerve palsy suggesting left VI cranial nerve damage in a 
teenager with Kallmann syndrome and a heterozygous CHD7 mutation (adapted from (162). 
(E) Ear pavilion abnormality suggesting CHARGE syndrome in a male CHH patient initially 
referred for Kallmann syndrome. (F) Inner ear CT scan showing patient’s semicircular canals 
hypoplasia in a male patient with Kallmann syndrome and deafness resulting from a 
heterozygous SOX10 mutation (adapted from (163) and (164)). (G) Post-natal kidney 
ultrasound, left posterior fossa view showing absent left kidney in a male neonate with an 
ANOS1 mutation (s=spleen). (H) Right kidney ultrasound in same patient revealing 
compensatory hypertrophy (dotted line indicates kidney length of 65 mm). (C and F) Maione 
L, Brailly-Tabard S, Nevoux J, et al. Letter to the editor: Reversal of congenital 
hypogonadotropic hypogonadism in a man with Kallmann syndrome due to SOX10 mutation. 
Clin Endocrinol (Oxf) 2016; 85:988-989. 
Figure 3. Hormone levels and ultrasound features in female CHH patients compared 
with healthy controls. Serum FSH and LH (panel A), estradiol (E2) (panel B) and serum 
ovarian peptides inhibin B (panel C), and AMH (panel D) levels in in untreated women with 
CHH (n = 68, aged from 18 to 34 years) and age-matched healthy young women (controls, n 
= 52). Mean ovarian volume (panel E), total mean antral follicle (AF) number /ovary (panel 
F) in untreated women with CHH (n = 39) and in healthy women (n = 41). Adapted with 
permission from Bry-Gauillard H, Larrat-Ledoux F, Levaillant J-M, et al. Anti-Mullerian 
hormone and ovarian morphology in women with isolated hypogonadotropic 
hypogonadism/Kallmann syndrome: effects of recombinant human FSH. J Clin Endocrinol 
Metab 2017; 102(4):1102-1111. 
Figure 4. Genetics in CHH. (A) Timeline of gene discovery in CHH and CHH-overlapping 
syndromes. (B) Biological involvement of CHH genes in GnRH neuronal system. CHH, 
congenital hypogonadotropic hypogonadism.  
Figure 5. Pedigrees and gene mutations in CHH and KS patients. All gene variants listed 
are rare (minor allele frequency <0.5%) and predicted to be damaging by standard protein 
prediction algorithms (SIFT and/or PolyPhen2). All variants are classified as pathogenic or 
likely pathogenic according ACMG recommendations (258). Pedigree 1: X-Linked 
Kallmann syndrome caused by ANOS1 mutation; Pedigree 2: autosomal recessive mode of 
inheritance; Pedigree 3: de novo mutation; Pedigree 4: autosomal dominant with reduced 
penetrance; Pedigree 5: oligogenic mutation with de novo mutation in FGF8.  Circles denote 
females; and squares denote males; arrows mark probands. A diagonal slash through a 
symbol means the subject is deceased. Regarding the gene mutations, + represents wild-type 
(reference) sequence, and a 0 is present in hemizygous male subjects for genes on the X 
chromosome. NA, not available.  
Figure 6. Practical algorithm of clinical management for patients with delayed puberty.  
SD, standard deviation; E2, estradiol; TV, testicular volume; T, testosterone; FSH, follicule 
stimulating hormone; LH, luteinizing hormone; INB, inhibin B; CHH, congenital 
hypogonadotropic hypogonadism; HH, hypogonadotropic hypogonadism; CDGP, 
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constitutional delay of growth and puberty. * TV increase under testosterone treatment or 
after therapeutic window highly indicate CDGP.  
Table 1. The prevalence of main non-reproductive phenotypes in CHH versus general 
population. 
Phenotypes 
All CHH KS General population 
Waldstreicher et al. 
(n = 106) (157) 
Quinton et al. 
(n = 215) 
(158) 
Quinton et al. 
(n = 112) 
(158) 
Costa-Barbosa et al. 
(n = 219) (160)  
Anosmia / hyposmia 55% 52% 100% 100% 0.01% 
Mirror movement NA 20% 31% 19% 0.0001% 
Unilateral renal 
agenesis NA 10% 15% 8% 0.05% 
Eye movement 
disorders 3% 20% 27% NA 0.02  - 0.0002% 
Hearing loss 6% 5% a 8% a 15% 0.02% 
Cleft lip/palate 7% 5% 4% 6% 0.1% (165) 
Dental agenesis NA NA NA 14% 4 - 7% (166) 
Syndactyly, 
polydactyly, 
camptodactyly 
NA NA NA 5% 
0.03  - 0.1% (167) 
0.2 - 1.3% (168) 
1% (169) 
Scoliosis NA NA NA 13% 0.05 - 0.1% (170) 
NA: not assessed; a only sensorineural hearing loss is included. Prevalence in the general population: anosmia 
data from NIH Genetic and Rare Disease Information Center (https://rarediseases.info.nih.gov/, accessed in 
January 2018); for mirror movement, eye movement disorders and hearing loss, data were obtained from NIH 
Genetics Home Reference (https://ghr.nlm.nih.gov, accessed in January 2018); unilateral renal agenesis data is 
from Orphanet (http://www.orpha.net/consor/cgi-bin/index.php, accessed in January 2018).  
Table 2. Complex syndromes with clinical & genetic overlap with CHH. 
Syndrome Major signs Minor signs Genetic overlap with CHH * 
CHARGE 
syndrome 
coloboma, choanal atresia, semi-
circular canal dysplasia 
hypothalamic-pituitary defect, 
sensorineural hearing loss, ear 
malformation, mental retardation, 
congenital heart defect 
CHD7 (162,171-174)  SEMA3E 
(175,176) 
Waardenburg 
syndrome 
sensorineural hearing loss, 
abnormal pigmentation 
hypogonadotropic hypogonadism, 
anosmia with OB aplasia/hypoplasia, 
facial dysmorphism, megacolon, semi-
circular canal dysplasia, congenital 
heart defect 
SOX10 (163,164,177,178) 
Hartsfield 
syndrome 
split-hand/foot malformation, 
holoprosencephaly 
anosmia, hypothalamic-pituitary 
defect, syndactyly, facial 
dysmorphism 
FGFR1 (179-182) 
Adrenal hypoplasia 
congenita 
hypogonadotropic 
hypogonadism, adrenal 
hypoplasia 
- NR0B1 (DAX1) (183,184) 
4H syndrome 
hypogonadotropic 
hypogonadism, hypodontia, 
hypomyelination 
- POLR3B (185,186) 
Septo-optic 
dysplasia 
optic nerve hypoplasia, 
hypothalamic-pituitary defect, 
midline brain defect  
- 
HESX1 (187,188) 
SOX2 (189-191) 
Phenotypes which overlap between these syndromes and CHH are highlighted in bold.  OB, olfactory bulb; 4H 
syndrome: hypomyelination, hypogonadotropic hypogonadism and hypodontia. * Genetic overlap with CHH: 
list of genes mutated in both syndromic and non-syndromic forms of CHH, with landmark studies cited as 
references. 
Table 3. Clinical and biochemical characteristics of neonatal CHH males reported in 
literature 
Case 
No. 
Clinical signs Hormonal testing 
Diagnosis Neonatal treatment References Neonatal signs Family history 
Age 
(months) 
T 
(nmol/L) 
LH 
(IU/L) 
FSH 
(IU/L) 
1 micropenis hyposmia 4 n.d. n.d. 0.18 CHH hCG, T (202) 2 ascending testis CPHD 3.5 n.d. 0.07 0.18 CPHD T 
3 micropenis none 0-7.9 n.d. n.d. 0.05- CHH rFSH + rLH, (203) 
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0.17 T 
4 micropenis n.r. 2 0.03 0.19 0.19 CPHD rFSH + rLH (204) 5 micropenis n.r. 3.5 0.06 0.03 0.12 CHH rFSH + rLH 
6 
micropenis, 
cryptorchidism, 
CLP, SHFM 
CHH, 
CLP 2 n.d. n.d. 0.4 CHH rFSH + rLH (207) 
7 micropenis KS 1 0.1 0.04 0.18 KS rFSH + rLH (136) 
8 micropenis, 
cryptorchidism none 3 0.3 n.d. n.d. CHH T (205) 
9 micropenis, 
cryptorchidism n.r. 6 0.2 0 0.4 CPHD rFSH + rLH 
(206) 
10 micropenis, 
cryptorchidism n.r. 4.5 0.2 0.4 1 CHH rFSH + rLH 
11 micropenis, 
cryptorchidism n.r. 2.5 0.1 0.1 0.8 CHH rFSH + rLH 
12 cryptorchidism n.r. 5 0.1 n.d. 0.3 CHH rFSH + rLH 
13 micropenis, 
cryptorchidism n.r. 0.25 0.2 n.d. 0.21 CHH rFSH + rLH 
T, testosterone; LH, luteinizing hormone; FSH, follicle stimulating hormone; n.r., not reported; CLP, cleft lip 
palate; hCG, human chorionic gonadotropin; rFSH, recombinant FSH; rLH, recominant LH; n.d., not detectable. 
Table 4. Medical treatment for puberty induction, hypogonadism and infertility in female 
CHH patients. 
Treatment Dosing & administration Advantage Disadvantages 
Induction of puberty in girls 
17b-estradiol 
(tablets) 
Initial dose: 5 µg/kg daily P.O. 
Natural estrogen Less preferable than transdermal 
route ↑ 5 µg/kg increments every 6-12 months  
Up to 1-2 mg daily 
17b-estradiol 
(patch) 
Inital dose: 0.05 - 0.07 µg/kg , only nocturnal  Natural estrogen 
Small dose patch not available, 
need to cut the patch of 25ug/24h ↑ to 0.08 - 0.12 µg/kg every 6 months 
No hepatic passage 
(decrease 
thromboembolic risk) 
Up to 50 - 100 µg/24 h  
Progesterone Added after full breast development or break-through bleeding, during the last 14 days of menstrual cycle   
Treatment of hypogonadism in adult females 
Estroprogestin 
therapy 
(tablets) 
17β-estradiol 1  or 2 mg  Mimic the 
physiological hormone 
changes 
 
Progestin: during the last 14 days of the months  
micronized progestin 200mg P.O. daily, or  
dydrogesterone 10 mg P.O. daily 
Estroprogesin 
therapy (patch 
or gel) 
17β-estradiol patch 50-100 ug/24h daily, OR 
Mimic the 
physiological hormone 
changes 
 
17β-estradiol gel 7.5 - 15 mg daily 
Progestin: during the last 14 days of the months  
micronized progestin 200mg P.O. daily, or  
dydrogesterone 10 mg P.O. daily 
Treatment of fertility in adult females 
Pulsatile 
GnRH 
I.V. pump: 75 ng/kg per pulse every 90 min Most physiological treatment Not available in many countries 
Dose adaped based on response, up to 500 ng/kg per 
pulse 
Possibility to adjust 
pulse frequency in I.V. 
pump 
Require centers with expertise 
S.C. pump: 15 µg per pulse every 90 min High success rate Risk of phlebitis for I.V. treatment (rare) 
Dose adapted based on response, up to 30 µg per pulse Less risk in multiple pregnancy Pituitary resistance (rare) 
Luteal phase: continue GnRH pump, OR   
HCG 1500 U every 3 days for 3 times   
Gonadotropins 
hMG (FSH + LH) 75 - 150 IU S.C. daily, dose adapted 
based on follicular growth 
Available around the 
world More expensive 
Induction of ovulation by hCG 6500 IU S.C. injection Self-injection Higher risk of overstimulation 
Luteal phase:   Requires close monitoring of E2 & US 
hCG 1500 U every 3 days for 3 times  Higher risk of multiple pregnancy  
Progesterone 200mg intravaginal daily   
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
e 
R
ev
ie
w
s
D
ow
nloaded from
 https://academ
ic.oup.com
/edrv/advance-article-abstract/doi/10.1210/er.2018-00116/5303368 by U
niversity of H
elsinki user on 01 February 2019
AD
VA
NC
E 
AR
TI
CL
E
Endocrine Reviews; Copyright 2019  DOI: 10.1210/er.2018-00116 
 
 
63
Table 5. Medical treatment for puberty induction, hypogonadism and infertility in male CHH 
patients. 
Treatment Dosing & administration Advantage Disadvantages 
Induction of puberty in boys 
Testosterone 
enanthate (TE) 
Initial dose: 50 mg  I.M. monthly Standard care with long clinical 
experience 
Premature epiphyseal closure (high 
dose) 
↑ 50 mg increments every 6 - 12 
months,  
Aromatizable to E2: promote 
bone maturation Could inhibit TV & spermatogenesis  
Up to 250 mg monthly  Impact on future fertility: unknown 
Gonadotropin 
hCG: initial dose 250 IU twice weekly, 
S.C. 
Stimulate TV growth & 
spermatogenesis Not standard treatment 
↑ 250 - 500 IU increments every 6 
months 
Pre-FSH treatment can be 
beneficial in patients with TV < 
4ml or history cryptorchidism 
Need good compliance in adolescent 
patients 
Up to 1500 IU 3 times weekly  Need studies in larger cohorts 
rFSH: dose 75-150 IU 3 times weekly, 
S.C.   
Hypogonadism treatment in adult males 
Testosterone 
enanthate (TE) 
250 mg I.M. every 2-4 weeks Cost effective Relative frequent I.M. injection 
Interval adjusted based on trough T Available around the world S.C. route is under investigation (302) 
 Self injection  
Testosterone 
undecanoate 
(TU) 
1000 mg I.M. every 10-14 weeks Cost effective 
Interval of treatment is highly 
variable, follow-up of trough T is 
important 
Interval adjusted based on trough T  Infrequent injection Injections by nurses 
Testosterone 
gel  50-80 mg transdermal daily 
Non invasive Risk of transmission by skin contact Self-administrated 
Treatment of infertility in adult males 
Pulsatile 
GnRH 
S.C. pump: 25 ng/kg per pulse every 
120 min 
Most physiological treatment 
Not available in many countries 
Dose adapted based on serum T Require centers with expertise 
Up to 600 ng/kg per pulse Pituitary resistance (rare) 
Gonadotropin 
hCG: dose 500-1500 IU 3 times weekly, 
S.C. Available around the world Relative expensive for rFSH 
Dose adjusted based on trough T For patients with absent puberty (TV < 4ml):  Frequent injections 
rFSH: dose 75-150 IU 3 times weekly, 
S.C. 
pre-rFSH treatment increases 
fertilty prognosis  
Dose adjusted based on serum FSH, 
sperm count   
Table 6. Fertility outcomes in male patients with congenital hypogonadotropic 
hypogonadism: summary of 44 published studies. 
Study # CH
H 
(n) 
nC
HH 
(n) 
KS 
(n) 
CHH 
with 
cryptor
chi-
dism (n) 
Media
n 
Basal 
TV 
(mL) 
Median 
Maximal 
TV (mL) 
Medi
an 
Max. 
Sper
m 
Coun
t 
(106/
mL) 
Medi
an 
TTS 
(mon
ths) 
Therapy 
failure 
(persiste
nt 
azoosper
mia) (n) 
Therapies 
used 
Pregnan
cies* (n) 
Reference 
Combined gonadotropin therapy        
1 10 8 2 NA NA NA NA 16 1 hMG+hCG 4 (368) 
2 36 25 11 NA NA NA 5.1 5 9 hPG 12 (369) 
3 15 7 8 7 NA NA 8.5 10 5 hMG+hCG 8 (370) 
4 13 7 6 4 2.4 6.9 1.3 11.5 1 hMG+hCG 2 (7) (371) 
5 13 13 0 0 1.2 3.1 3.0 NA 2 hMG+hCG 3 (372)) 
6 24 17 7 Excluded 6.8 13.9 16.7 7.6 
not 
included hMG+hCG 22 (250) 
7 8 NA NA NA 2.1 9 1.0 24 2 hMG + hCG 1 (8) (373)
+
 
8 18 9 9 5 2.5 8 4 12 9 hMG+hCG 1 (374)++ 
9 16 8 8 4 3.5 13.3 6.0 23.1 2 hMG+hCG NA (375) 
10 18 NA NA Excluded 3.7 14.9 2.6 34.2 4 hCG+hMG 7 (10) (376) 
11 10 4 6 Exclude 4 12 18.5 24 NA hMG+hCG 3 (4) (377) 
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d 
12 7 6 1 6 1.2 9 10.0 11.8 1 hMG+hCG 3 (378) 
13 9 7 2 0 2.2 8 8.0 14 2 hMG+hCG 4 (379) 
14 26 12 14 13 1.5 3.8 2.2 12.2 12 hMG+hCG 3 (380) 
15 35 19 16 Excluded 4.3 11.1 14.0 5 12 uFSH+hCG 1 (4) (381) 
16 27 16 11 Excluded 3.6 10.5 16.5 9 3 uFSH+hCG 2 (10) (382) 
17 18 9 9 8 4.4 15.3 1.2 6 2 hMG+hCG 3 (383)+++ 
18 10 8 2 Excluded 3.5 9.6 5.0 6.6 2 
rhFSH+hC
G 2 (384) 
19 26 17 9 Excluded 2 12 1.5 9 4 
rhFSH+hC
G 4 (7) (385) 
20 20 13 7 5 8 NA 5 5.5 NA rhFSH / 
uFSH+hCG NC (386) 
21 9 8 1 4 3 7.5 5.1 16.8 NA hMG+hCG NA (387) 
22 26 11 15 11 5.7 12 5.0 7 10 rhFSH+hCG NA (388) 
23 23 18 5 9 1.6 4.85 1.0 52 7 hMG+hCG NA (389) 
24 4 4 0 0 4.1 6.8 2.05 12 0 hMG +hCG 3 (390) 
25 4 2 2 2 1 5.5 3.0 10 1 rhFSH+hCG NA (330) 
26 25 16 9 Excluded NA 14 5.2 5.1 1 
rhFSH+hC
G 5 (30) (391) 
27 77 48 29 Excluded 3.4 11.7 8.2 18 13 
rhFSH+hC
G 14 (51) (392) 
28 51 34 17 12 6.5 NA 8.0 23 NA rhFSH / 
uFSH+hCG 38 (393) 
29 10 9 1 0 NA 9 7.0 9.8 1 
hMG / 
rhFSH+hC
G 
4 (394) 
30 31 22 9 Excluded 3.8 9 22.8 12 NA 
rhFSH / 
uFSH 
+hCG 
10 (22) (395) 
31 19 8 11 9 4.5 10.2 7.1 11 1 hMG+hCG 5 (11) (396) 
32 223 112 111 40 2.1 8.1 11.7 15 80 hMG+hCG 17 (397) 
33 38 18 20 19 2.5 16.5 15.0 55 3 rhFSH+hCG 0 (325) 
Sub-
Total 899 515 358 158     190  181*  
Pulsatile GnRH therapy        
34 5 3 2 NA 3 4.5 4.1 3 3 GnRH 1 (364) 
35 10 6 4 NA NA NA 4.2 12 1 GnRH 3 (398) 
36 30 NA NA 0 5 18 68 5 1 GnRH 18 (30) (399) 
37 5 NA NA NA 2.4 11.5 0.1 24 3 GnRH 2 (5) (373)+ 
38 10 8 2 1 4 14 19.2 12 0 GnRH NA (366) 
39 18 10 8 4 2 10 4.7 5 4 GnRH 1 (374)++ 
40 28 17 11 13 2 12 2 10.7 7 GnRH 3 (400) 
41 6 4 2 3 6.8 14.9 1.6 4 1 GnRH 3 (383)+++ 
42 52 26 26 21 3.3 12 15.0 24 9 GnRH NA (66) 
43 35 12 23 9 2.3 9 NA 12 9 GnRH NA (401) 
44 20 9 11 4 2.9 10.8 14.2 15.6 NA GnRH 5 (14) (402) 
Sub-
Total 219 95 89 55     38  36*  
Total, n 1118 610 447 213     228  217*  
Mean     3.4 9.8 7.59 15.3     
Weighte
d 
mean** 
    3.51 10.8 9.83 15.2     
CHH: congenital hypogonadotropic hypogonadism; n= number of male CHH patients; nCHH: CHH without 
reported Kallmann syndrome features; KS: patients with Kallmann syndrome;  
TV: mean testicular volume; TTS: time to induce sperm appearance in ejaculate (months);  
Therapies used: FSH-preparations used in combination with chorionic gonadotropin (hCG): hMG: human 
menopausal gonadotropin (FSH+LH); uFSH: urinary highly purified FSH; rhFSH: recombinant human FSH; 
hPG: human pituitary gonadotropin (mixture of FSH and LH); GnRH: gonadorelin (pulsatile administration via 
a pump). 
Excluded: CHH/KS patients with cryptorchidism excluded from the study design.  
NA: not available; NC: non calculable 
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Data are reported as number or medians, as appropriate.  
Please note that, because of the wide range of some parameters (notably sperm count, which may range from 
0.01 to >300 million/mL), we chose to show medians instead of means. 
*Pregnancies obtained (number in parentheses indicate the total number of patients treated who wished 
paternity). 
 ** To underline the importance of the populations’ size, we also calculate the weighted means of these medians 
(i.e. we calculated weighted means of 8,489.9 106/mL (patients x sperm count), and 10,341.4 mL (patients x 
testicular volumes)). The weighted means are then divided on the total number of patients whom these numbers 
refer (respectively 864 for the sperm count and 956 for the testicular volumes). 
+, ++ and +++: data from the same study. 
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